anand kumar md - umanitoba.ca · anand kumar md current professor of medicine (2014 - present)...

1

Anand Kumar MD

current Professor of Medicine (2014 - present)

academic Section of Critical Care Medicine

position Section of Infectious Diseases Department of Medicine Department of Medical Microbiology

Department of Pharmacology and Therapeutics University of Manitoba

Winnipeg, Manitoba, Canada

Research Director, Section of Critical Care Medicine (2011-present)

University of Manitoba Winnipeg, Manitoba, Canada

previous

academic

positions 1994-1996 Instructor, Section of Pulmonary and Critical Care Medicine

Department of Medicine University of Wisconsin Hospital and Clinics Madison, Wisconsin 1996-2002 Assistant Professor of Medicine

Section of Critical Care Medicine Section of Infectious Diseases

Department of Medicine Rush University, Chicago, Illinois 1997-1998 Acting Director, CCM Fellowship Program

Section of Critical Care Medicine Department of Medicine Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois 1996-2001 Associate Director, CCM Fellowship Program

Section of Critical Care Medicine Department of Medicine Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois

2

2001-2005 Assistant Professor of Medicine Section of Critical Care Medicine

Section of Infectious Diseases Department of Medicine Department of Medical Microbiology

Department of Pharmacology and Therapeutics University of Manitoba

Winnipeg, Manitoba, Canada

2003-2014 Associate Professor of Medicine Section of Critical Care Medicine Section of Infectious Diseases Cooper Hospital/University Medical Center

University of Medicine and Dentistry, New Jersey Camden, New Jersey

education 1975-1980 Dunbarton High School, Pickering, Ontario, Canada valedictorian; top graduate Durham Region 1980 (22 high schools) 1980-1982 B.A. (incomplete) Faculty of Arts and Science, University of Toronto, Ontario, Canada 1982-1986 M.D., Faculty of Medicine, University of Toronto, Ontario, Canada

postgraduate

training 1986-1987 Comprehensive Medical Internship

Toronto General Hospital University of Toronto, Ontario, Canada

1987-1988 Internal Medicine Residency Year Two, Toronto General Hospital 1988-1989 Internal Medicine Residency Year Three, Toronto Western Hospital

University of Toronto, Ontario, Canada 1989-1990 Critical Care Medicine Fellowship Year One,

3

Health Sciences Centre and St. Boniface Hospital, University of Manitoba, Winnipeg, Manitoba, Canada 1990-1992 Critical Care Medicine Fellowship Year Two and Three Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA 1992-1993 Cardiovascular Research Fellowship Section of Cardiology and Critical Care Medicine Department of Medicine Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois, USA 1993-1994 Infectious Diseases Fellowship Year One (research) Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois, USA 1994-1996 Infectious Diseases Fellowship Year Two and Three (clinical) University of Wisconsin Hospital and Clinics Madison, WI, USA

work

experience 1988-1989 House Medical Officer (wards/CCU/MICU/SICU) Toronto East General Hospital, Toronto, Ontario, Canada 1988-1989 House Medical Officer and Casualty Officer (emergency/CCU/ICU), St. Joseph's Health Centre Toronto, Ontario, Canada 1989-1990 House Medical Officer (CCU/MICU/SICU) Health Sciences Center, Winnipeg, Manitoba, Canada 1989-1990 House Medical Officer (CCU/MICU/SICU) St. Boniface General Hospital, Winnipeg, Manitoba, Canada 1989-1990 Emergency Transport Physician, Provincial Air Ambulance

Winnipeg, Manitoba, Canada 1990-1991 Instructor -Clinical Methods for Year 2 students Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois

4

August Instructor, Section of CCM/Faculty of Medicine 1991 University of Manitoba

Attending Staff, St. Boniface Hospital, Winnipeg, Manitoba, Canada August Attending Staff, Medicine and ICU, McKellar General Hospital 1992 Thunderbay, Ontario, Canada 1994-1996 Attending Staff and Instructor, Trauma-Life Support Unit University of Wisconsin Hospital and Clinics Madison, Wisconsin 1996-2001 Attending Physician

Section of Critical Care Medicine Department of Medicine Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois 1996-2001 Attending Physician, MICU Cook County Hospital Chicago, Illinois 2001-present Attending Staff MICU and SICU, Health Sciences Centre ICM and ICS, St. Boniface Hospital ICU, Concordia Hospital ICU, Grace Hospital Winnipeg, Manitoba, Canada 2004-present Director of Research, Critical Care Medicine University of Manitoba Winnipeg Manitoba

board Diplomate of the National Board of Medical

certification Examiners 1987 Licenciate of the Medical Council of Canada 1987 Diplomate of the American Board of Internal Medicine 1989

Fellow of the Royal College of Physicians and Surgeons (Canada) as Specialist in Internal Medicine 1990

Completion of Royal College accredited program in Critical Care Medicine 1991

5

Board certified, Critical Care Medicine, American Board of Internal Medicine 1992

Board certified, Infectious Diseases American Board of Internal Medicine 1996

training Basic Cardiac Life Support (BCLS) Instructor

certification American Heart Association 1981-1986 Advanced Cardiac Life Support (ACLS) Instructor American Heart Association 1987-1991

Fundamentals of Critical Care Support (FCCS) Instructor Society of Critical Care Medicine 1998-present

medical Manitoba, Canada, #13-459

licensure New Jersey, USA, #25MA07704000 Wisconsin, USA (inactive) #35401

Ontario, Canada (inactive) #56799 Illinois, USA (inactive) #36080287

professional Fellow, American College of Critical Care Medicine

organizations Fellow, American College of Chest Physicians Member, Society of Critical Care Medicine Member, Canadian Critical Care Society

Member, Shock Society Member, Royal College of Physicians and Surgeons

(Canada)

professional Critical Care Medicine, Infectious Diseases and Microbiology,

interests Sepsis and septic shock, Nosocomial infections

research clinical studies :assessment of cardiovascular dysfunction in sepsis and other critical illness using nuclear ventriculography and echocardiography

characteristics and outcomes of a multinational cohort of septic

shock cases (Cooperative Antimicrobial Therapy of Septic Shock Database)

6

characteristics of 2009 pandemic H1N1 influenza A infection

small animal projects –time dependent survival, cardiovascular physiology (echocardiography, conductance catheter techniques), transcriptional regulation (EMSA) and gene expression (gene array techniques) responses in murine models of septic shock using endotoxin and peritoneal implantation of an infected clot (with Aseem Kumar, PhD) differential endotoxin/cytokine release and hemodynamic effects in response to different classes and combinations of antibiotics in mouse and rat models of septic shock (clot implant)

bench laboratory projects -assessment of the effect of novel antimicrobial dosing strategies on bacterial clearance, cytokine generation, hemodynamic function and survival in a rodent model of E.coli peritonitis-induced septic shock assessment of novel antimicrobial dosing strategies on bacterial clearance and endotoxin generation in a in-vitro model of bacterial infection

Graduate Amarnath Pisapati, PhD Microbiology 2015

Students The use of ultra-high dose aminoglycoside in experimental rat septic shock

Noha Al-Kurdi, MSc Microbiology 2011

Antimicrobial pharmacodynamics against MRSA in an in vitro infection model: Comparing monotherapy to combinations under standard and altered conditions

Khalil Meghairbi, MSc Microbiology 2012

The association of antibiotic pharmacodynamic indices with survival in human septic shock

Ehsan Koohpayehzadeh, MSc pharmacology 2014 The effect of ultra-high doses of Gentamicin on resistant pathogenic bacteria in an in vitro pharmacodynamic model: A viable approach in life-threatening infections with septic shock Gloria Vasquez-Grande,MD PhD Microbiology (in program) The impact of antibiotic sequence on bacterial kill in a rat infected peritoneal clot implant model of septic shock

7

Anton Kowalski, BSc MSc Microbiology (in program) The impact of antagonistic antimicrobial combinations on outcome in experimental murine and spontaneous human septic shock

BSc Med Cheryl Peters, MD 2008

Students Initiation of inappropriate antimicrobial therapy results in a 5-fold reduction of survival in human septic shock (published Chest 2009)

Laura Kravetsky, MD 2008 Combination antimicrobial therapy yields improved survival

compared to monotherapy in septic shock: A propensity-matched analysis (published Crit Care Med 2010)

Harleena Gulati, MD 2005

Systemically administered heparin is associated with increased survival in patients diagnosed with septic shock (published Crit Care Med 2007)

multicentre Principal Site Investigator. Multiple dose safety, tolerability,

clinical studies pharmacokinetics and pharmacodynamics of PMX 622 in patients with severe SIRS and evidence of infection. Novartis. 1997-1998

Sub-investigator - A Pivotal Phase II/III, multicenter, randomized, controlled, parallel group study of the HepaAssistTM Liver Assist System compared to standard SICU care in patients with acute hepatic failure. Circe Biomedical. 1996-1997

Member: Medic Trial, Clinical Evaluation Committee Elan Pharmaceuticals. 2000-2001. Principal Site Investigator (Health Sciences Centre, St. Boniface Hospital) Canadian Fungal Infection Survey: A Point Prevalence Study. Fujisawa and Co, 2004 Principal Site Investigator (Health Sciences Centre, St. Boniface General Hospital and Grace General Hospital, Winnipeg Manitoba). Phase III trial of EMD 20001 (LIPOS) in patients with severe sepsis and evidence of infection. GlaxoSmithKline. 2004-2006.

8

Principal Site Investigator (St. Boniface Hospital, Winnipeg, MB) The ACCESS trial. A controlled comparison Eritoran tetrasodium and placebo in patients with severe sepsis. Eisai, Inc 2006-2009. Principal Site Investigator (Health Sciences Centre, Winnipeg, MB) Safety and efficacy of TAK -242 in adults with severe sepsis (Phase II/III trial). Takeda, Inc. 2006-2007. Principal Site Investigator (Health Science Centre, Winnipeg, MB) PROWESS-SHOCK: A Randomized, placebo-controlled trial of Drotrecogin Alfa (Activated) for the treatment of septic shock. Eli Lilly Co. 2008-2011.

Chair, Clinical Evaluation Committee. ProBac: Use of Procalcitonin level as part of a decision tree to discontinue antibiotics when started empirically in the ICU in hemodynamically stable patients with no site of infection identified. Brahms AG, 2008-2009. Principle Site Investigator (Health Sciences Centre and St. Boniface Hospitals) Open-label, non-comparative study of intravenous anidulafungin followed optionally by oral voriconazole or fluconazole therapy, for treatment of documented candidemia/invasive candidiasis in intensive care unit patient ppulation. Pfizer and Co, 2009-present. Principle Site Investigator (Health Sciences Centre and St. Boniface Hospitals) Efficacy and safety of Eraxis/Ecalta (anidulafungin) compared to Cancidas (caspofungin) in patients with candida deep tissue infections: A phase 4 study. Pfizer and Co. 2009-2012. Principle Site Investigator (St. Boniface Hospital and Health Sciences Centre) The OASIS Study: Talactoferrin for the treatment of severe sepsis - a Phase II/III trial. Aggenix Co. 2010-2012 Principle Site Investigator (Health Sciences Centre and St. Boniface Hospital) CYTOFAB: Efficacy and safety of anti-TNF-alpha polyclonal antibody fragment (Fab) with placebo in adult patients with severe sepsis and/or septic shock. Astra-Zeneca Inc. 2010-2012 Steering Committee. Heparin anticoagulation to reduce death in septic shock: a multicentre interventional study. CIHR. 2012-present

9

academic J.W. Billes Open Admission Scholarship 1980-1984

honors Faculty of Arts and Science 1980-1982 Faculty of Medicine 1982-1984 University of Toronto Alpha Omega Alpha Medical Honor Society, 1983-1985 Young Investigator Award

Shock Society 1993 Canadian Critical Care Society Arrow Young Investigator Award 1993 (best original research)

American Federation for Clinical Research

Trainee Investigator Award 1993 Robert M Kark Prize (best original research) Chicago Society of Internal Medicine 1993 Young Investigator Educational Scholarship Award (outstanding original research by a fellow or junior faculty) Society of Critical Care Medicine 1993

DuPont Pharmaceuticals/ACCP Young Investigator Award (outstanding research by a fellow)

American College of Chest Physicians 1993 DuPont Pharmaceuticals/ACCP Critical Care Research Award Finalist American College of Chest Physicians 1993 Cecile Lehman Mayer Award Finalist (best basic research presentation and manuscript) American College of Chest Physicians 1993 Internal Medicine Specialty Award (best research) Society of Critical Care Medicine 1994 American Federation for Clinical Research 1994 Trainee Investigator Award Canadian Critical Care Society Arrow Young Investigator Award 1994 (best original research)

10

In-Training Young Investigator Award (best abstract and manuscript by fellow or junior faculty)

Society of Critical Care Medicine 1995

Smith-Kline Beecham SHEA/CDC Hospital Epidemiology Training Program Scholarship 1996

Young Investigator Award (best abstract and manuscript by faculty) Society of Critical Care Medicine 1998 Best Abstract, 2

nd place

As senior author (1st author John Ronald)

Toronto Critical Care Medicine Symposium 2004 Soffer Award for best abstract nominee As senior author (1

st author Sat Sharma)

American College of Chest Physicians 2004 Internal Medicine Award (best abstract in Internal Medicine) Society of Critical Care Medicine 2005 Finalist, Best Abstract As senior author (1

st author Ryan Zarychanski)

Toronto Critical Care Medicine Symposium 2005 Finalist, Best Research As senior author (1

st author Smita Pahkale)

Society of Critical Care Medicine 2006 Winner, Infection Specialty Award As senior author (1

st author Faisal Siddiqui)

Society of Critical Care Medicine 2008

competitive Society of Critical Care Medicine Research Fellowship 1992

grant Effect of inflammatory cytokines on contractility and metabolism of

support isolated cardiac myocytes ($50,000)

Medical Research Council of Canada Research Fellowship Award 1993-94. Role of inflammatory cytokines in human septic serum-induced depression of isolated cardiac myocytes ($50,000 renewable salary support) -renewal declined for 1994-95

11

Manitoba Medical Services Foundation Grant 2004 ($25,000)

Continuous versus intermittent -lactam antibiotic infusion in severe sepsis: a randomized pilot study Manitoba Medical Services Foundation, Winnipeg, Canada Lilly Sepsis Research Grant 2004 ($60,000): A retrospective review of a geographically comprehensive cohort of septic shock patients from 1999-2003. Innovations and Opportunities Grant 2004 ($25,000)

Continuous versus intermittent -lactam antibiotic infusion in severe sepsis: a randomized pilot study Health Sciences Centre, Winnipeg, Canada Canadian Intensive Care Foundation Grant 2005 ($20,000)

Continuous versus intermittent -lactam antibiotic infusion in severe sepsis: a randomized pilot study University of Manitoba Research Grant 2005 ($7500) Antibiotic PK/PD determinants of outcome in human septic shock. St. Boniface Hospital and Research Foundation 2005 ($30,000) Ultra high dose aminoglycoside therapy for experimental septic shock in mice and rats Health Sciences Centre Foundation 2005 ($35,000) A retrospective review of critical management-related determinants of outcome in septic shock Manitoba Health Research Council Establishment Grant 2008 ($100,000). Optimization and development of novel antimicrobial strategies for therapy of septic shock Public Health Agency of Canada. 2009-2010 ($350,000): Assessment of cytokine response and virus clearance in epidemic H1N1-associated critical illness Co-investigator, Canadian Institutes of Health Research. Catalyst Grant 2009-2011: Pandemic Outbreak Research Response ($600,000). Influenza-and H1N1-Related Critical Illness - Demand and Capacity in the Health Care System: the Canadian ICU Flu Study (PI Robert Fowler, MD) Co-investigator. Public Health Agency of Canada. 2009-2011

12

($400,000): Influenza-and H1N1-Related Critical Illness - Demand and Capacity in the Health Care System: the Canadian ICU-Flu Study (Co-PIs, Robert Fowler and Dr. Philippe Jouvet). Co-investigator, Canadian Institutes of Health Research. Operating Grant 2011 ($228,000). Strategies for Protecting Vulnerable Canadian Populations from Emerging Infectious Diseases (PI, Syed Moghadas, PhD) Co-applicant, Canadian Institutes of Health Research. Operating Grant 2011 ($100,000). Heparin anticoagulation to reduce death in septic shock (HALO pilot) (PI, Ryan Zarychanski, MD) Co-investigator, Manitoba Health Research Council. Operating Grant 2011 ($100,000). Heparin anticoagulation to reduce death in septic shock (HALO pilot) (PI, Ryan Zarychanski, MD) Co-investigator, Canadian Institutes of Health Research. Networks of Centers of Excellence Program 2012-2017 ($23,888,157). Technology Evaluation in the Elderly Networks (Tech Value Net). (PI, Daren Heyland) Co-investigator, Philippine Council for Health Research and Development, Operating Grant 2016-2018 ($200,000). Heparin anticoagulation to reduce death in septic shock (HALO international phase IIb) (PI, Marissa Alejandro, MD)

Co-PI, Canadian Institutes of Health Research, Project Scheme Grant 2017-2019 ($645,000). Heparin anticoagulation to reduce death in septic shock (HALO international phase IIb) (Co-PI, Ryan Zarychanski, MD and Dean Fergusson, PhD)

other grants Merck Unrestricted Research Grant 1999 ($8000): Effect of antibiotics selection on cardiovascular performance in a murine model of septic shock.

Pfizer Unrestricted Research Grant 2000 ($8000): Effect of antibiotics selection on survival in a murine model of septic shock. Ortho-McNeil Unrestricted Research Grant 2000 ($10,400): Effect of antibiotic selection on endotoxin and cytokine generation in a murine model of septic shock. ABbiodisk, Inc Grant 2004 ($5000 material support):

13

Pharmacokinetic/pharmacodynamic indices predict outcome in human septic shock. Merck Unrestricted Research Grant 2004 ($10,000): Assessment of therapeutic determinants of outcome in a comprehensive cohort of septic shock. Pfizer Unrestricted Research Grant 2005 ($15,000): Assessment of therapeutic determinants of outcome in septic shock. Astellas Canada Unrestricted Research Grant 2005 ($10,000): Assessment of antimicrobial administration delay as a cause of excessive mortality in fungal septic shock. Astellas US Unrestricted Research Grant 2005 ($15,000): Assessment of antimicrobial administration delay as a cause of excessive mortality in fungal septic shock. Bristol-Myers-Squibb Unrestricted Research Grant 2005 ($10,000): Effect of different resuscitative fluids and volumes on outcome in human septic shock. AstraZeneca Unrestricted Research Grant 2005 ($3500): Critical determinants of outcome in human septic shock. Bayer Unrestricted Research Grant 2005 ($10,000): Assessment of therapeutic determinants of outcome in human septic shock. Wyeth Unrestricted Research Grant 2006 ($12,500): Assessment of antimicrobial determinants of outcome in human septic shock. Pfizer Unrestricted Research Grant 2008 ($20,000): A propensity matched analysis of combination versus mono-antimicrobial therapy of septic shock. Pfizer Unrestricted Research Grant 2009 ($20,000): A retrospective review of a comprehensive cohort of fungal septic shock Roche Pharmaceuticals 2009 ($365,000): Relative oral bioavailability of oseltamivir in ill patients with respiratory failure in the intensive care unit: an investigator-initiated study. Roche Pharmaceuticals 2009-2011 ($3,250,000): A randomized, double-blinded controlled trial comparing high vs standard dose oseltamivir in severe influenza infection in the ICU: an investigator-

14

initiated, multi-centre study. Collaborative Matching Support: Public Health Agency of Canada 2009-2011 Astellas Pharmaceuticals 2009 ($30,000): A retrospective review of a comprehensive cohort of septic shock. Assessment of critical determinants of outcome in Candida septic shock. Astellas Pharmaceuticals 2009-2012 ($120,000): A retrospective review of a comprehensive cohort of fungal septic shock. Impact of echinocandin therapy on outcome. Astellas Pharmaceuticals 2010-2011 ($70,000). Astellas Fellowship in Antifungal Research. Fellowship support for 1 year of research training for Shravan Kethireddy, MD Glaxo-Smith-Kline (GSK) 2011-2013 ($50,500). Severe pandemic H1N1 infection in ICU: Comparative resource utilization. Glaxo-Smith-Kline (GSK) 2011-2013 ($50,000). Severe pandemic H1N1 infection in ICU: Pulmonary pathological disease progression in fatal H1N1 pneumonia Pfizer 2011-2012 ($20,000) Comparison of MRSA monotherapies to combinations under standard and septic shock infection site conditions in an in-vitro infection model

committees Class of 1986 (Medicine) representative to University of Toronto Student Council 1985, Toronto, Ontario, Canada

Toronto General Hospital Antibiotic Use Committee 1987 Toronto, Ontario, Canada

Graduate Medical Education Evaluation Committee, 1989-90 University of Manitoba, Winnipeg, Manitoba, Canada Director, Quality Assurance, Division of Cardiology/CCM Rush-Presbyterian-St. Luke’s Medical Center, 1996-2001 Nosocomial Pneumonia Process Improvement Committee Rush-Presbyterian-St. Luke’s Medical Center, 1996-1997 Society of Critical Care Medicine Research and Awards Committee, 1998-2000

15

Department of Medicine, Quality Assurance Committee 1999-2002 Rush-Presbyterian-St. Luke’s Medical Center Medical Care Evaluation Committee 1999-2001

Credentials Committee, 2001-2003 American College of Critical Care Medicine

American Board of Internal Medicine/Society of Critical Care Medicine Educational Project Committee 2002 Chairs: Donald Chafin, MD and Antoinette Spevetz, MD

Planning Committee, Rocky Mountain Critical Care Conference. Silver Star Mountain Resort, BC, Canada. February 19-22, 2003

Abstract Review Committee, Society of Critical Care Medicine Annual Scientific Symposium 2003-2010

Member, International Scientific Review Committee Eli Lilly Research Grants Program 2003-2004

Member, Continuing Education Committee, 2003-2005 Society of Critical Care Medicine Planning Committee, Rocky Mountain Critical Care Conference. Banff Resort, BC, Canada. February 17-20, 2004

Vice Chair, Credentials Committee, 2004 American College of Critical Care Medicine Chair, Credentials Committee, 2005-2007 American College of Critical Care Medicine Member, On-line Education Committee Society of Critical Care Medicine 2005-2007 Organizing Committee Public Health Agency of Canada Conference Severe H1N1 Disease: Preventing Cases; Reducing Mortality Sept 2-3, 2009, Winnipeg, MB

Physician Advisory Committee St. Boniface Hospital/Winnipeg Regional Health Authority 2010-2015

16

Antimicrobial Stewardship Committee Winnipeg Regional Health Authority 2010-2016 Organizational Committee Antimicrobial De-escalation Symposium University of Manitoba, Sept 15, 2012 Sepsis Working Group (Information Systems Update) Winnipeg Regional Health Authority 2014-present Group Head, Infection Management

Surviving Sepsis Campaign International Guidelines for the Management of Severe Sepsis and Septic Shock 2016 Guideline Writing Committee 2014-2017

course Fundamentals of Critical Care Support

participation Rush-Presbyterian-St. Luke’s Medical Center 1997, 1998, 1999, 2000, 2001

University of Wisconsin at Madison 1999, 2000, 2001 Cadaveric Procedure Course University of Wisconsin 1995, 1996, 1997, 1998, 1999, 2000, 2001 Rush-Presbyterian-St. Luke’s Medical Center 2002 University of Manitoba 2003-2005

ad-hoc reviewer Critical Care Medicine Gastroenterology Chest JAMA Journal of Heart and Lung Transplantation Journal of Molecular and Cellular Cardiology American Journal of Physiology

Journal of Applied Physiology Clinical Infectious Diseases

American Journal of Respiratory and CCM Circulation Research Cytokine

17

Cardiovascular Research Journal of Applied Physiology Archives of Internal Medicine Annals of Internal Medicine Intensive Care Medicine Journal of Infectious Diseases Canadian Medical Association Journal (CMAJ) Annals of Emergency Medicine Journal of Infection BMC Immunology Annals of Emergency Medicine Scandinavian Journal of Infectious Diseases European Respiratory Journal Critical Care Thorax Journal of Critical Care Clinical Microbiology and Infection

original research manuscripts 1) Kumar A, Devlin HR, Vellend H: Pasteurella multocida meningitis in an adult: Case report and review. Reviews of Infectious Diseases 1990;12:440-448 2) Kumar A, Minuk G: Post-infantile giant cell hepatitis in association with hypereosinophilia. Gastroenterology 1991;101:1417-1419 3) Kumar A, Wong N, Bow E, Sutton D: Thrombotic thrombocytopenic purpura in association with human immmunodeficiency virus infection. Case report and review. Canadian Journal of Infectious Diseases 1992;3:37-41 4) Kumar A, Kamanpuhzha P: Pasteurella multocida septic arthritis. Southern Medical Journal 1992;85:329-331 5) Kumar A, Bleck T: Intravenous midazolam for the treatment of refractory status epilepsy. Critical Care Medicine 1992;20:483-488 6) Kumar A: Massive gastrointestinal hemorrhage due to esophageal candidiasis. Southern Medical Journal 1994;87:669-671

7) Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE: Tumor necrosis factor- and

interleukin-1 are responsible for depression of in-vitro myocardial cell contractility induced by serum from humans with septic shock. Journal of Experimental Medicine

18

1996;183:949-958 8) Goldfarb RD, Glock D, Kumar A, McCarthy RJ, Mei J, Guynn T, Matushek M, Trenholme G, Parrillo JE: A porcine model of peritonitis and bacteremia simulates human septic shock. Shock 1996;6:442-451. 9) Kumar A: Intravenous amiodarone for atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. Southern Medical Journal 1996;89:779-785. 10) McGill M, Kumar A, Rahko P: Venous air embolism: Echocardiographic diagnosis of left-sided air bubbles in a patient with previously diagnosed intrapulmonary shunt. Chest 1997;111:826-828 11) Kahl BS, Kumar A, Hale SJ, Hart MN, Badr S: Hantavirus pulmonary syndrome in Wisconsin. Wisconsin State Medical Journal 1997;96:33-6 12) Kumar A, Parrillo JE: Divergent effects of epinephrine and amrinone on contractility and cyclic AMP generation of TNF-exposed cardiac myocytes. Crit Care Med 1999;27:286-292. 13) Kumar A, Kandula P, Brar R, Dee L, Uretz E, Parrillo JE: The role of nitric oxide and cyclic GMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol 1999;276:R265-R276. 14) Pahwa R, Kumar A: Persistent left superior vena cava: an intensivist's experience and review of the literature. Southern Medical Journal. 2003;96:528-9. 15) Paladugu B, Kumar A, Parrillo JE, Der S, Osman J, Mensing J, Falvo L, Kumar A: Bacterial DNA and RNA depress contractility of rat cardiac myocytes. Shock 2004;21:364-369 16) Kumar A, Anel A, Bunnell E, Zanotti S, Habet K, Haery C, Marshall S, Neumann A, Ali A, Kavinsky C, Parrillo JE: Preload-independent mechanisms are partially responsible for improved cardiac output following large volume saline infusion in normal volunteers. Critical Care 2004;8:R128-R136 17) Kumar A, Anel R, Bunnell E, Habet K, Neumann A, Wolff D, Rosenson R, Cheang M, Parrillo JE: Effect of large volume infusion on left ventricular volumes, performance and contractility parameters in normal volunteers. Intensive Care Med 2004;30:1361-1369. 18) Kumar A, Anel R, Bunnell E, Habet K, Zanotti S, Marshall S, Neumann A, Ali A, Kavinsky C, Cheang M, Parrillo JE. PWP and CVP fail to predict ventricular filling

19

volume, cardiac performance or the response to volume infusion in normal subjects. Crit Care Med. 2004:32;691-699 19) Kumar A, Bunnell G, Lynn M, Anel R, MD, Habet K, Neumann A, Cheang M, Parrillo JE: Experimental human endotoxemia is associated with depression of load-independent contractility indices: Prevention by the lipid A analogue, E5531. Chest 2004;126:860-867 20) Kumar A, Zanotti S, Bunnell G, Habet K, Anel R, Neumann A, Cheang M, Cutler D, Parrillo JE: Interleukin-10 administration blunts the pro-inflammatory cytokine and metabolic response without affecting hemodynamic response to endotoxin challenge in healthy volunteers. Crit Care Med 2005;33:331-340 21) Arabi Y, Kumar A, Wood KE, Flaten A: The feasibility of nitric oxide delivery with high frequency jet ventilation. Respirology 2005;10:673-677 22) Kumar Aseem, Kumar Anand, Michael P, Brabant D, Parissenti AM, Ramana CV Xu X, Parrillo JE: Human septic serum derived from patients undergoing sepsis

activates transcription factors STAT1, IRF1, NF-B and induces apoptosis in human myocytes J Biol Chem 2005;280:42619-26 23) Kumar Anand, Paladugu B, Haery C, Kumar Aseem, Symeoneides S, Taiberg, Osman J, Trenholme G, Opal S, Goldfarb R, Parrillo JE: Timing of antibiotic administration in relation to duration of hypotension is a critical determinant of survival in a murine model of E. coli septic shock: Association with serum lactate and inflammatory cytokines. Journal of Infectious Diseases 2006;193:251-8

24) Kumar Anand, Roberts D, Wood KE, Light RB, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar Aseem, Cheang M: Duration of hypotension prior to initiation of effective antimicrobial therapy is a critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-1596 25) Kumar Anand, Paladugu B, Mensing J, Kumar Aseem, Parrillo JE: Nitric oxide-dependent and –independent mechanisms are involved in TNFα-induced depression of cardiac myocyte contractility. Am J Physiol 2007;292:R1900-R1906. 26) Kumar Anand, Paladugu B, Kumar Aseem, Mensing J, Parrillo JE. Transforming

growth factor-1 blocks in-vitro cardiac myocyte depression by tumor necrosis factor,

interleukin-1 and human septic serum. Crit Care Med 2007:35:358-364. 27) Aarts MW, Brun-Buisson C, Cook DJ, Kumar A, Opal S, Rocker G, Smith T, Vincent J-L, Marshall JC: Antibiotic management of suspected nosocomial ICU-acquired infection: Does prolonged empiric therapy improve outcome? Intensive Care Med. 2007;33:1369-1378

20

28) Kumar Anand, Schupp E, Bunnell E, Ali A, Milcarek B, Parrillo JE: Cardiovascular response to dobutamine predicts outcome in severe sepsis and septic shock. Critical Care 2008;12:R35-R46 29) Falvo L, Michael P, Xu X, Parrillo JE, Omri A, Kumar Anand and Kumar Aseem. Human septic serum induced apoptotic gene expression profile in human myocytes. In Cell Apoptosis Research Progress (as a refereed paper) Editor: Robert H. Fenton pages 135-152, May 2008, Nova Publishing. 30) Zarychanski R, Gulati H, Roberts D, Sharma S, Houston DS, Kumar A: Systemically administered heparin is associated with increased survival in patients diagnosed with septic shock. Crit Care Med 2008;36:2973-2979 31) Tessier M, Michael P, Brabant D, Chilakamarti RV, Omri A, Saleh M, Parrillo JE, Kumar Anand and Kumar Aseem. Identification of factors in septic sera utilizing antibody arrays. In Recent Advances in Biochemical and Biophysical Research (as a refereed paper). Editor: Ramana V. Chilakamarti. pages 1-23, May 2008, Research Signpost. 32) Bagshaw S, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood W, Ellis P, Guzman J, Marshall J, Parrillo JE, Skrobik Y, Kumar A, and the CATSS Database Research Group. Acute Kidney Injury in Septic Shock: Clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Medicine 2009:35:871-881.

33) Hussein S, Michael P, Parissenti A, Omri A, Kumar A, Parrillo JE and Kumar A. Characterization of human septic sera induced gene expression modulation in human myocytes. Int J Clin Exp Med 2009;2(2):131-48 34) Kumar A, Ellis P, Arabi Y, Roberts D, Light RB, Parrillo JE, Dodek PE, Wood G, Kumar A, Peters C, Chateau D and the CATSS Database Research Group. Initiation of inappropriate antimicrobial therapy results in a 5-fold reduction of survival in human septic shock. Chest 2009;136:1237-1248. 35) Kumar A, Zarychanski R, Pinto R, Cook D , Marshall J, Lacroix J , Stelfox T, Bagshaw S, Choong K, Lamontagne F, Turgeon AF, Lapinsky S , Ahern SP, Smith O, Siddiqui F, Jouvet P, Khwaja K, McIntyre L, Menon K, Hutchison J, Hornstein D, Joffe A, Lauzier F, Singh J, Karachi T, Wiebe K, Olafson K, Ramsey C, Sharma S, Dodek P, Meade M, Hall R and Robert Fowler for the Canadian Critical Care Trials Group H1N1 Collaborative. Critically Ill Patients with Novel Swine Origin Influenza Virus A/H1N1 Infection in Canada. JAMA 2009;302(17):1872-1879 36) Smetanin P, Stiff D, Kumar A, Kobak P, Zarychanski R, Simonsen N, Plummer F. Potential ICU ventilator demand/capacity mismatch due to novel pandemic (2009)

21

H1N1 infection in Canada: Impact of a national vaccination strategy. Canadian Journal of Infectious Diseases 2009; 20(4):e114-e123. 37) Zarychanski R, Stuart TL, Doucette S, Elliot L, Kumar A, Kettner J, Plummer F. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010;182:257-64. 38) Mousavi N, Czarnecki A, Ahmadie R, Fang T, Kumar K, Lytwyn M, Kumar A, Jassal DS. The utility of tissue Doppler imaging for the noninvasive determination of left ventricular filling pressures in patients with septic shock. J Intensive Care Med 2010;25:163-167. 39) Freed DH, Henzler D, White CW, Fowler R, Zarychanski R, Hutchison J, Arora RC, Manji RA, Legare JF, Drews T, Veroukis S, Kesselman M, Guerguerian AM, Kumar A and the Canadian Critical Care Trials Group. Extracorporeal lung support for patients who had severe respiratory failure secondary to influenza A (H1N1) 2009 infection in Canada. Canadian Journal of Anesthesia 2010;57:240-7 40) Oluyom-Obi T, Avery L, Menticoglou S, Schneider C, Kumar A, Lapinsky S, Zarychanski R. Perinatal and maternal outcomes in critically ill obstetric patients with pandemic H1N1 Influenza A. Journal of Obstetrics and Gynecology 2010;32(5):443–447 41) Stiff D, Kumar A, Kissoon N, Fowler R, Jouvet P, Skippen P, Smetanin P, Kesselman M, Veroukis S. Potential pediatric ICU demand/capacity mismatch due to novel H1N1 in Canada. Pediatric Critical Care Medicine 2011;12(2):e51-e57 doi: 10.1097/PCC.0b013e3181e2a4fe 42) Ariano RE, Sitar DS, Zelenitsky SA, Zarychanski R, Pisapati A, Ahern S, Kanji S, Rello J, Kumar A. Enteric absorption and pharmacokinetics of oseltamivir in pandemic H1N1 influenza (2009) associated critical illness. CMAJ 2010; 182:357-63.

43) Sood MM, Rigatto C, Zarychanski R, Komenda P, Sood AR, Bueti J, Reslerova M, Roberts D, Mojica J, Kumar A. Acute kidney injury in critically ill patients infected with pandemic H1N1 influenza A: Report from a Canadian province. Am J Kid Dis 2010;55:848-855

44) Jouvet P, Hutchison J, Pinto R, Menon K, Rodin R, Choong K, Kesselman M, Veroukis S, Dugas MA, Santschi M, Guerguerian A-M, Withington D, Alsaati B, Joffe A, Drews T, Skippen P, Rolland E, Kumar A, Fowler R, Canadian Critical Care Trials Group H1N1 Collaborative. Critical illness in children with influenza A/H1N1 2009 infection in Canada. Pediatric Critical Care Medicine 2010;11(5);603-9

45) Hajjar L, Mauad T, Galas FRBG, da Silva LFF, Dolhnikoff M, Trielli T, Almeida JP, Borsato MRL, Abdalla E, Pierrot L, Filho RK, Auler JOC Jr, Saldiva PHN, Hoff PM,

22

Kumar A. Severe novel influenza A (H1N1) infection in cancer patients. Annals of Oncology 2010;21(12):2333-41 doi:10.1093/annonc/mdq254 46) Kumar A, Safdar N, Kethireddy S, Chateau D. The survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study. Critical Care Medicine 2010;38:1651-1664 47) Kumar A, Zarychanski R, Light RB, Parrillo JE, Maki DG, Simon D, Laporta D, Lapinsky S, Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood W, Arabi Y, Feinstein D, Kumar A, Dodek P, Kravetsky L, Doucette S and the CATSS Database Research Group. Combination antimicrobial therapy yields improved survival compared to monotherapy in septic shock: A propensity-matched analysis. Critical Care Medicine 2010;38:1773-1785 48) Keynan Y, Juno J, Meyers A, Ball TB, Kumar A, Rubinstein E, et al. Chemokine receptor 5 Δ32 allele in patients with severe pandemic (H1N1) 2009. Emerg Infect Dis. 2010;16:1521-2 49) Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, Du B, McArthur C, Myburgh J, the SAFE TRIPS Investigators (including Kumar A). Resuscitation fluid use in critically ill adults: an international cross sectional study in 391 intensive care units. Critical Care 2010;14:R185 50) Richardson JS, Abou MC, Tran KN, Kumar A, Sahai BM, Kobinger GP. Impact of systemic or mucosal immunity to Adenovirus on ad-based Ebolavirus vaccine efficacy in guinea pigs. J Inf Dis 2011;204: S1032-S1042. 51) Brabant D, Michael P, Narain R, Saleh M, Kumar A, Parrillo JE, Kumar A. Sepsis-mediated cellular dysfunction is mediated by DFF-induced apoptosis. Biochemical and Biophysical Research Communications 2011;412:260-5 52) La D, Czarnecki C, El-Gabalawy H, Kumar A, Meyers A, Plummer FA, Luo M. Enrichment of KIR3DL1/S1 alleles and HLA-B Bw6 homozygotes among H1N1/09 ICU patients: an exploratory study. PLoS ONE 2011:6(12): e29200. doi:10.1371/journal.pone.0029200 53) Cinel I, Ark M, Kubat H, Karabacak T, Serinol H, Tamer L, CinelL, Oral U, Michael P, Hussein S, Dellinger P, Parrillo JE, Kumar A, Kumar A. Involvement of Rho kinase (ROCK) in the sepsis-induced acute lung injury. J Thorac Dis 2012;4(1):30-39. Aug 10. DOI: 10.3978/j.issn.2072-1439.2010.08.04 54) Graham RG, Liang B, Van Domselaar G, Bastien N, Beaudoin C, Tyler S, Kaplen B, Landry E, Kumar A, Drews S, Fonseca K, Steppan P, Van Caaseele P, Cole R, Garceau R, Savoie S, Butt K, Stead F, Hatchette TF, Charest H, Bangura H, Li Y.

http://ccforum.com/content/14/5/R185

http://ccforum.com/content/14/5/R185

23

Nationwide Molecular Surveillance of Pandemic H1N1 Influenza A Virus Genomes: Canada, 2009. PLoS ONE. 2012;6(1): e16087. doi:10.1371/journal.pone.0016087 55) Olafson K, Zarychanski R, Kumar A. Sedation use in patients with respiratory failure associated with H1N1 infection: A comparison to respiratory failure due to bacterial pneumonia-related ARDS and other viral pneumonias. Annals of Pharmacotherapy 2012;46:9-20. DOI 10.1345/aph.1Q446.

56) Rimmer E, Kumar A, Doucette S, Marshall J, Dial S, Gurka D, Dellinger P, Sharma S, Penner C, Kramer A, Wood KE, Ronald J, Zarychanski R and The Co-operative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Activated Protein C and septic shock: A propensity-matched cohort study. Critical Care Medicine 2012:40;2074-2981.

57) Arabi YM, Dara SI, Memish Z, Al-Abdulkareem A, Tamim HM, Al-Shirawi N, Parrillo JE, Lapinsky S, Feinstein D, Wood G, Dial S, Kumar A for the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Antimicrobial therapeutic determinants of outcomes in patients with cirrhosis-associated septic shock. Hepatology 2012:56;2305-2312 58) Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: Importance of empiric therapy and source control. Clin Inf Dis 2012;54:1739-1746. 59) Bleiblo F, Michael P, Brabant D, Ramana CV, Tai TC, Saleh M, Parrillo JE, Kumar Anand, Kumar Aseem. Bacterial RNA induces myocyte cellular dysfunction through the activation of PKR. Journal of Thoracic Diseases 2012;4(2):114-125. 60) Funk D, Kumar A. Inhaled nitric oxide in patients with the acute respiratory distress syndrome secondary to Influenza A (H1N1) 2009 infection in Canada. Can J Anesthesia 2013;60(2);212-213 61) Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y, Kumar A and the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Vancomycin pharmacodynamics and survival in patients with methicillin–resistant Staphylococcus aureus (MRSA)–associated septic shock. International Journal of Antimicrobial Agents 2013: 41 (2013) 255–260 62) Bleiblo F, Michael P, Ramana CV, Tai TC, Saleh M, Parrillo JE, Kumar Anand, Kumar Aseem. JAK Kinases are required for the bacterial RNA and poly I:C-induced tyrosine phosphorylation of PKR. International Journal of Clinical and Experimental Medicine 2013;6(1):16-25. 63) Arabi YM, Dara SI, Tamim HM, Rishu AH, Bouchama A, Khedr MK, Feinstein D, Parrillo JE, Wood KE, Keenan S, Zanotti S, Martinka G, Kumar A, Kumar A and the

24

CATSS Database Research Group. Clinical characteristics, sepsis interventions and outcomes in the obese patients with septic shock: An international multicenter cohort study. Critical Care 2013;17:R72 64) Kethireddy S, Bruce Light RB, Miranejad Y, Maki D, Arabi Y, Lapinsky S, Simon D, Kumar A, Parrillo JE, Kumar A for the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Group. Mycobacterium tuberculosis septic shock. Chest 2013;144:474-82. 65) Muscedere J, Ofner M, Kumar A, Long J, Lamontagne F, Cook D, McGeer A, Chant C, Marshall J, Jouvet P, Fowler R for the ICU-FLU Group and the Canadian Critical Care Trials Group. The occurrence and impact of bacterial and fungal organisms complicating critical care illness associated with influenza A (H1N1) infection. Chest 2013;144:39-47. 66) Bleiblo F, Michael P, Brabant D, Ramana CV, Tai1 TC, Saleh M, Parrillo JE, Kumar Anand, Kumar Aseem. Immunostimulatory RNA Induces cardiac transcriptional factors and modulates cytokine expression profiles. Int J Curr Microbiol App Sci 2014;3(11):606-616 67) Leligdowicz A, Dodek PM, Norena M, Wong H, Kumar Aseem, Kumar Anand: The association between source of infection and hospital mortality in patients who have septic shock. Am J Respir Crit Care Med 2014;189:1204-13. 68) Sood MM, Shafer LA, Ho J, Reslerova M, Martinka M, Keenan S, Dial S, Wood G, Rigatto C, Kumar A, and the Cooperative Antimicrobial Therapy in Septic Shock (CATSS) Database Research Group. Early reversible acute kidney injury in septic shock is associated with improved survival. Journal of Critical Care 2014:29;711-717. 69) Sood M, Mandelzweig K, Rigatto R, Tangri N, Komenda P, Martinka G, Arabi Y, Keenan S, Kumar Aseem, Kumar Anand for the Cooperative Antimicrobial Therapy in Septic Shock (CATSS) Database Research Group. The site of infection but not the etiologic pathogen is associated with the occurrence and severity of AKI in septic shock. Intensive Care Medicine 2014:40;1080-1088. 70) Beck V, Chateau D, Bryson GL, Pisapati A, Zanotti S, Parrillo JE, Kumar A. Timing of Vasopressor Initiation and Mortality in Septic Shock: A Cohort Study. Critical Care 2014: 2014:18:R97. 71) Waechter J, Kumar A, Lapinsky SE, Marshall J, Dodek PE, Arabi Y, Parrillo JE, Dellinger RP, Garland A. Interplay Between Fluids and Vasoactive Agents on Mortality in Septic Shock: A Multicenter, Observational Study. Crit Care Med 2014;42:2158-2168.

25

72) Funk D, Doucette S, Dodek PE, Marshall J, Kumar A. Low Dose Corticosteroid Treatment in Septic Shock: A Propensity Matching Study. Crit Care Med 2014;42:2333-2341. 73) Rimmer E, Houston BL, Kumar A, About-Setta AM, Friesen C, Rock G, Turgeon AF, Cook DJ, Houston DS, Zarychanski R. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: A systematic review and meta-analysis. Critical Care 2014;18:699. 74) Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A, Houston DS, Rimmer E, Houston BL, McIntyre L, Fox-Robichaud AE, Hébert P, Cook DJ, Fergusson DA for the Canadian Critical Care Trials Group. The efficacy and safety of heparin in patients with sepsis: A systematic review and meta-analysis. Crit Care Med 2015;43;510-518. 75) Bednarczyk JM, Kethireddy S, White CW, Freed DH, Singal R, Bell D, Ahmed SZ, Kumar A, Light B: Extracorporeal membrane oxygenation for blastomycosis related acute respiratory distress syndrome: a case series. Can J Anes 2015; 62:807-815. 76) Fowler RA, Abdelmalik P, Wood G, Foster D, Gibney N, Bandrauk N, Turgeon AF, Lamontagne R, Kumar A, Zarychanski R, Green R, Bagshaw SM, Stelfox HT, Foster R, Dodek P, Shaw S, Granton J, Lawless B, Hill A, Rose L, Adhikari NK, Scales DC, Cook DJ, Marshall JM, Martin C, Jouvet P for the Canadian Critical Care Trials Group. Critical Care Capacity in Canada: Results of a National Cross-Sectional Study. Critical Care 2015;19:133. 77) Vincent J-L, Marshall JC, Dellinger RP, Simonson SG, Guntupalli K, Levy MM, Singer M, Malik R for the Oral Talactoferrin in Severe Sepsis Study Investigators (includes Anand Kumar). Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral Talactoferrin in Severe Sepsis Trial. Crit Care Med 2015; 43:1832–1838 78) Daneman N, Rishu AH, Xiong W, Bagshaw SM, Cook DJ, Dodek P, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall JC, Martin CM, McIntyre L, Muscedere J, Reynolds S, Stelfox HT, Fowler RA and the Canadian Critical Care Trials Group. Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): study protocol for a pilot randomized controlled trial. Trials 2015;16:173 79) Arabi YM, Aldawood AS, Haddad SH, Al-Dorzi HM, Tamim HM, Jones G, Mehta S, McIntyre L, Solaiman O, Sakkijha MH, Sadat M, Afesh L and the PermiT Trial Group (includes Anand Kumar). Permissive underfeeding or standard enteral feeding in critically ill adults. N Engl J Med 2015; 372:2398-2408 80) Karvellas CJ, Abraldes JG, Arabi Y, Kumar A and the Cooperative Antimicrobial Theray of Septic Shock (CATSS) Database Group. Appropriate and timely antimicrobial therapy in cirrhotic patients with spontaneous bacterial peritonitis-

26

associated septic shock: a retrospective cohort study. Alimentary Pharmacology and Therapeutics 2016; 41:747–757 81) Daneman N, Rishu AH, Xiong W, Bagshaw SM, Dodek P, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall J, Martin CM, McIntyre L, Muscedere J, Reynolds S, Stelfox HT, Cook DJ, Fowler RA. Duration of antimicrobial treatment for bacteremia in Canadian critically ill. Crit Care Med 2016;44:256-264 82) Delaney JW, Burns KEA, Burry LD, Griesdale D, Hutchison J, Jouvet P, Kumar A, Lamontagne F, Long J, Marshall J, Mehta S, Menon K, Pinto R, Fowler RA. Corticosteroids in the treatment of Influenza A 2009 (H1N1pdm09)-related critical illness. Crit Care 2016;20:75 83) Clark E, Kumar A, Langote A, Lapinsky S, Dodek P, Kramer A, Wood G, Bagshaw SM, Wood K, Gurka D, Sood M and the CATSS Database Research Group. Septic shock in chronic dialysis patients: clinical characteristics, antimicrobial therapy and mortality. Intensive Care Med 2016; 42:222–232 84) Savage RD, Fowler RA, Bagshaw SM, Cook D, Dodek P, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall J, Martin CM, McIntyre L, Muscedere J, Reynolds S, Rishu AH, Stelfox HT and Daneman N. The Effect of Inadequate Initial Empiric Antimicrobial Treatment on Mortality in Critically Ill Patients with Bloodstream Infections: A Multi-Centre Retrospective Cohort Study. PLoS ONE 2016;11(5): e0154944. doi:10.1371/journal.pone.0154944 85) Amaral ACKB, Fowler RA, Pinto R, Rubenfeld GD, Ellis P, Bookatz

B, Marshall J,

Martinka G, Keenan

S, Laporta

D, Roberts

D, Kumar A and the Cooperative

Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Patient and organizational factors associated with delays in antimicrobial therapy for septic shock. Crit Care Med 2016;44: 2145-2153 86) Savage RD, Fowler

RA, Rishu AH, Bagshaw

SM, Cook

D, Dodek P, Hall

R, Kumar

A, Lamontagne F, Lauzier F, Marshall J, Martin CM, McIntyre L, Muscedere J, Reynolds S, Stelfox HT, Daneman N. Pathogens and antimicrobial susceptibility profiles in critically ill patients with bloodstream infections: a descriptive study. CMAJ Open 2016. DOI:10.9778/cmajo.20160074 87) Funk D, Kumar A, Klar G. Decreases in cerebral saturation in patient with septic shock are associated with increased risk of death: a prospective observational single center study. J Intensive Care 2016;4:42

88) Arabi YM, Aldawood AS, Al-Dorzi HM, Tamim HM, Haddad SH, Jones G, Mehta S, McIntyre S, Solaiman O, Sakkijha MH, Sadat M, Afesh L, Kumar A, Bagshaw SM for the PermiT trial group. Permissive Underfeeding or Standard Enteral Feeding in High

27

and Low Nutritional Risk Critically Ill Adults. Am J Resp Crit Care Med 2017; 195:652–662 89) Tang BM,

Shojaei M, Parnell G, Huang S, Nalos M, Teoh S, O’Connor K, Schibeci

S, Phu AL, Kumar Anand, Ho J, Meyers AFA, Keynan Y, Ball T, Pisipati A, Kumar

Aseem, Moore E, Eisen D, Lai K, Gillett M, Geffers R, Luo H, Gul F, Schreiber J, Riedel S, Booth D, McLean A, Schughart K. A novel immune biomarker IFI27 discriminates between influenza and bacteria in patients with suspected respiratory infection. European Respiratory Journal 2017; 49:1602098 90) Banoei MM, Vogel H, Weljie A, Kumar A, Yende S, Angus DC, Winston B. Plasma metabolomics for diagnosis and prognosis of mortality of H1N1 influenza pneumonia Critical Care 2017;21:97 91) Poliquin P, Biondi M, Ranadheera C, Hagan M, Bello A, Racine T, Allan M, Funk D, Hansen G, Hancock B, Kesselman M, Mortimer T, Kumar A, Jones S, Leung A, Grolla A, Tran K, Tierney K, Qiu X, Kobasa D, Strong JE. Delivering Prolonged Intensive Care to a Non-human Primate: A High Fidelity Animal Model of Ebola Virus-Associated Critical Illness. Scientific Reports (Nature) 2017;7;1204 doi: 10.1038/s41598-017-01107-6. 92) Bednarczyk JM, Fridfinnson JA, Kumar A, Blanchard L, Rabbani R, Bell D, Funk D, Turgeon AF, Abou-Setta AM, Zarychanski R. Incorporating dynamic assessment of fluid responsiveness into goal-directed therapy: A systematic review and meta-analysis. Critical Care Medicine 2017 (in press)

93) Jung J, Long J, Pinto R, Zarychanski R, Cook DJ, Jouvet P, Marshall JC, Kumar A, Rodin R, Fowler RA. 2009-2010 H1N1-related critical illness among aboriginal and non-aboriginal Canadians. Submitted PlosONE 94) Kethireddy S, Bilgili B, Bengier A, Kirchner L, Ofoma UR, Light RB, Mirzanejad Y, Maki D, Kumar A, Layon AJ, Parrillo JE, Kumar Anand and the Antimicrobial Therapy of Septic Shock (CATSS) Database Group. Culture Negative Septic Shock Compared To Culture Positive Septic Shock: A Retrospective Cohort Study. Critical Care Medicine 2017 (in press) 95) Page AV, Darwish I, Conroy AL, Kumar A, Liles WC. Elevated systemic biomarkers of endothelial activation in critically ill patients with confirmed or suspected pandemic influenza A(H1N1) virus infection (submitted) 96) Peters C, Dodek PE, Norena M, Wong H, Ayas N, Leligdowicz A, Kumar A and the Co-operative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Mortality in Septic Shock is Associated with Time from Hypotension to Ordering and Ordering to Administration of Antimicrobials (submitted)

28

97) Pisipati A, Esfahani EH, Gutierrez O, Zhanel GG, Kumar A. Activity of supranormal doses of gentamicin against susceptible and non-susceptible Gram-positive and Gram-negative bacteria in an in-vitro pharmacodynamics model (submitted)

98) Kumar Anand, Zarychanski R, Pisipati A, Kumar Aseem, Kethireddy S, Bow EJ. Fungicidal vs Fungistatic Therapy of Invasive Candida Infection in Non-Neutropenic Adults: A Meta-Analysis (submitted)

99) Rolfes MA, Gross FL, Glannery B, Meyers AFA, Luo M, Bastien N, Fowler RA, Katz JM, Levine MZ, Kumar A, Uyeki TM. Kinetics of serological responses in critically ill patients hospitalized with influenza A(H1N1)pdm09 virus infection in Canada, 2009–2011. Submitted to Journal of Infectious Diseases. 100) Daneman N, Rishu A, Pinto R, Aslanian P, Bagshaw SM, Carignan A, Charbonney E, Coburn B, Cook DJ, Detsky ME, Dodek P, Hall R, Kumar A, Lamontagne F, Laurier F, Marshall JC, McIntyre L, Muscedere L, Reynolds S, Sligl W, Stelfox HT, Elizabeth E, Fowler RA. 7 versus 14 days of Antibiotic Treatment for Critically Ill Patients with Bloodstream Infection: A Pilot Randomized Clinical Trial. Submitted to Critical Care 101) Roberts R, Duprey M, Kumar A, Devlin J. Initiation of an Antibiotic with Methicillin-Resistant Staphylococcus Aureus Coverage before an Antibiotic with Pseudomonas Aeruginosa Coverage is Associated with Greater Mortality in Septic Shock. Submitted to Intensive Care Medicine

102) Tang BM, Shojaei M, Teoh S, Ho J, Meyers A, Ball T, Keynan Y, Pisipati A, Kumar

A, Eisen D, Lai K, Gillett M, Santram R, Huang S, Parnell G, Nalos M, Geffers R,

Schreiber J, Riedel S, Mozhui K, Booth D, Kumar A, McLean A, Schughart K. The genomic landscape of influenza infection: Network clustering of host response reveals key drivers of disease progression to fatality. Submitted to Am J Resp Crit Care Med.

103) Kok B, Karvellas CJ, Albrades JG, Jalan R, Sundaram R, Gurka D, Keenan S, Kumar Aseem, Martinka G, Bookatz B, Wood G, Kumar Anand and the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. The impact of obesity in cirrhotic patients with septic shock: a retrospective cohort study. Submitted to Alimentary Pharmacology and Therapeutics. 104) Karvellas CJ, Dong V, Abraldes JG, Kumar A and the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. The impact of delayed source control and antimicrobial therapy in 196 patients with cholecystitis-associated septic shock. Submitted to Hepatology.

edited volumes and books

29

1) Kumar A, Parrillo JE. Guest Editors, Critical Care Clinics. Historical Aspects of Critical Care Medicine and Critical Illness. Elsevier Saunders 2009;25(1)

2) Kumar A, Farmer C. Guest Editors. H1N1 Novel Influenza: Pandemic Issues for Critica Care Practitioners. Critical Care Medicine. April 2010;38(4) 3) Kumar A. Guest Editor, Critical Care Clinics. Optimizing Antimicrobial Therapy of Sepsis and Septic Shock. Elsevier Saunders 2011;27(1)

4) Kumar A. Guest Editor. Critical Care Clinics. Life-Threatening Infections I. Elsevier Saunders 2013;29(2) 5) Kumar A. Guest Editor. Critical Care Clinics. Life-Threatening Infections II. Elsevier Saunders 2013;29(3) 6) Molnar Z, Giamarellos-Bourboulis E, Nierhaus A, Kumar A. Guest Editors. Biomed Research International. Special Issue: Sepsis - Diagnostic and Therapeutic Challenges. 2016

chapters, invited reviews, editorials and letters 1) Section Editor, Infectious Diseases: Medical Council of Canada Qualifying Exam (MCCQE) Review Notes and Lecture Series 1986 (2nd edition). Editors, Mark C. Miller, George L. Kruzyk. University of Toronto Press 2) Contributing editor: Yearbook of Critical Care Medicine 1991 Editors: JE Parrillo MD and M Rogers MD Mosby Yearbook Publications 3) Contributing editor: Yearbook of Critical Care Medicine 1992 Editors: JE Parrillo MD and M Rogers MD Mosby Yearbook Publications 4) Kumar A, Parrillo JE: Clinical manifestations of cardiovascular dysfunction in sepsis. In Pathophysiology of Shock, Sepsis and Organ Failure. Editor: Gunther Schlag and Heinz Redl. Springer-Verlag Publications 1993 5) Contributing editor: Yearbook of Critical Care Medicine 1993 Editors: JE Parrillo MD and M Rogers MD Mosby Yearbook Publications 1993 6) Contributing editor: Yearbook of Critical Care Medicine 1994 Editors: JE Parrillo MD and M Rogers MD

30

Mosby Yearbook Publications 1994 7) Kumar A, Parrillo JE: Shock: Classification, pathophysiology, and approach to management. In Textbook of Critical Care Medicine. Editors: Roger Bone and Joseph E. Parrillo. Mosby Publications 1995 8) Kumar A, Parrillo JE: Myocardial depression in septic shock: Role of nitric oxide and other mediators. In Proceedings of the Fourth Wiggers Bernard Conference on Shock, Sepsis, and Organ Failure. Editor: G Schlag and DL Traber. Springer-Verlag Publications 1995 9) Kumar A, Parrillo JE: Nitric oxide and the heart. In Update in Intensive Care and Emergency Medicine Volume 23: Role of nitric oxide in sepsis and ARDS. Series Editor: JL Vincent, Volume Editors: MP Fink and D Payen. Springer Verlag Publications 1995. 10) Kumar A: Management of infections in the immunosuppressed. In Critical Care Medicine: Perioperative Management. Editors: Michael J. Murray, Douglas B. Coursin, Ronal G. Pearl, and Donald S. Prough. Lippincott-Raven Press 1996. 11) Kumar A, Wood KE: Hypovolemic and hemorrhagic shock. In Current Therapy in Critical Care Medicine. Editor: JE Parrillo. Mosby Publications 1997. 12) Kumar A, Parrillo, JE: The heart in sepsis: The role of nitric oxide in septic myocardial depression. In Yearbook of Intensive Care and Emergency Medicine 1997. Editor: JL Vincent. Springer Verlag Publications 1997. 13) Kumar A: Central nervous system infections. In Society of Critical Care Medicine Board Review Manual 1997. Editor: J Zimmerman. SCCM Publications 1997. 14) Kumar A: Cardiovascular Pharmacology: Inotropes, vasopressors and vasodilators. In Society of Critical Care Medicine Board Review Manual 1997. Editor: J Zimmerman. SCCM Publications 1997. 15) Kumar A: Inotropes and gut mucosal perfusion: A brake on the motor of multiple organ failure? Crit Care Med 1997;25:1266-1267 16) Kumar A, Symoneides S: Life-threatening infections in the immunosuppressed. In Society of Critical Care Medicine Refresher Course Manual 1998. Editor: J Zimmerman. SCCM Publications 1998. 17) Contributing Editor: Fundamental Critical Care Support Course Text. Second Edition. A Standardized Curriculum of the Principles of Critical Care Medicine. Editors: RP Dellinger et al. Society of Critical Care Medicine Publications 1998.

31

18) Kumar A: Catheter related infections. In Handbook of Hemodynamic Monitoring. Editors: Gloria Darovic, R.N. and Corey Franklin, M.D. W.B. Saunders 1999. 19) Kumar A: Antimicrobials in the ICU: Beyond Bugs and Drugs. In Society of Critical Care Medicine Refresher Course Manual 1999. Editor: Pamela Roberts. SCCM Publications 1999. 20) Kumar A: Nosocomial and ventilator-associated pneumonia. In Society of Critical Care Medicine Refresher Course Manual 1999. Editor: Pamela Roberts. SCCM Publications 1999 21) Kumar Anand, Kumar Aseem, Parrillo JE: Cytokines and septic myocardial depression: Nitric oxide vs. Sphingosine/ceramide? Crit Care Med June 1999;27:1391-1393. 22) Kumar A, Short J, Parrillo JE: Genetic Factors in Septic Shock. JAMA 1999;282:579-581. 23) Kumar A: The dobutamine oxygen flux test: A road map to outcome in sepsis? Crit Care Med 1999;27:2571-2572.

24) Kumar A, Haery C, Parrillo JE: Cardiac manifestations of sepsis: Role of cytokines and nitric oxide. Critical Care Clinics of North America 2000;16:251-288.

25) Kumar A, Haery C, Parrillo JE: Myocardial dysfunction in septic shock, Part I: Clinical manifestations of cardiovascular dysfunction in septic shock. Journal of Cardiothoracic and Vascular Anesthesia 2001;15:364-376. 26) Kumar A, Krieger A, Symoneides S, Parrillo, JE: Myocardial dysfunction in septic shock, Part 2: Role of cytokines and nitric oxide. Journal of Cardiothoracic and Vascular Anesthesia 2001:15;485-511 27) Landgarten MJ, Kumar A, Parrillo JE: Cardiovascular dysfunction in sepsis and septic shock. Current Treatment Options in Cardiovascular Medicine 2000;2:451-459. 28) Contributing editor: Yearbook of Critical Care Medicine 2001 Editors: RP Dellinger MD, JE Parrillo MD, RA Balk MD, JE Calvin MD, Cory Franklin MD and BA Shapiro MD. Mosby Yearbook Publications 2001. 29) Kumar A, Parrillo JE: Shock: Classification, pathophysiology, and approach to management. In Textbook of Critical Care Medicine. 2

nd Edition. Editors: Joseph E.

Parrillo, MD and R. Phillip Dellinger, MD. Mosby Publications 2001.

32

30) Kumar A, Krzyda E, Darovic GO: Chapter 13: Infusion-related sepsis. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 3

rd Ed.

Editor: Gloria Oblouk Darovic, RN. WB Saunders 2002. 31) Kumar A, Darovic GO: Chapter 8: Establishment of Central Venous Access. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 3

rd Ed.

Editor: Gloria Oblouk Darovic, RN. WB Saunders 2002. 32) Darovic GO, Kumar A: Chapter 9: Monitoring Central Venous Pressure. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 3

rd Ed.

Editor: Gloria Oblouk Darovic, RN. WB Saunders 2002. 33) Anel R, Kumar A: Fungal Infections and Resistance. In Society of Critical Care Medicine Refresher Course Manual 2001. Editor: P Roberts. SCCM Publications 2001. 34) Hota B, Kumar A: Management of infections in the immunocompromised. In Critical Care Medicine: Perioperative Management. 2

nd Edition. Editors: Michael J.

Murray, Douglas B. Coursin, Ronald G. Pearl, and Donald S. Prough. Lippincott, Williams and Wilkins, 2002. 35) Kumar A, Calvin J, Parrillo JE: Critical Care Research. In Critical Care Medicine: Perioperative Management. 2

nd Edition. Editors: Michael J. Murray, Douglas B.

Coursin, Ronald G. Pearl, and Donald S. Prough. Lippincott, Williams and Wilkins 2002. 36) Zanotti S, Kumar A: Primum (non nocere) lavate manus. Critical Care Medicine 2001;29:458-459. 37) Osman J, Kumar A: Septic myocardial depression: No "no" to NO? Critical Care Medicine 2001;29:202-203. 38) Anel R, Kumar A: Experimental and emerging therapies for sepsis and septic shock: Part 1. Coagulation modulators, NO inhibitors, complement and steroids. Expert Opinion in Investigational Drugs 2001;10:1471-1485. 39) Zanotti S, Kumar Aseem, Kumar Anand:.Experimental and emerging therapies for sepsis and septic shock: Part 2. Cytokine modulation in sepsis and septic shock. Expert Opinion in Investigational Drugs 2002;11:1061-1075. 40) Manocha S, Feinstein D, Kumar Aseem, Kumar Anand: Experimental and emerging therapies for sepsis and septic shock: Part 3. Anti-endotoxin strategies in gram-negative sepsis and septic shock. Expert Opinion in Investigational Drugs 2002;11:1795-1812.

33

41) Contributing editor: Yearbook of Critical Care Medicine 2002 Editors: RP Dellinger MD, JE Parrillo MD, RA Balk MD, JE Calvin MD, Cory Franklin MD and BA Shapiro MD. Mosby Yearbook Publications 2002. 42) Krishnagopalan S, Kumar Aseem, Parrillo JE, Kumar Anand: Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care 2002;8(5):376-388. 43) Court O, Kumar Aseem, Parrillo JE, Kumar Anand: Myocardial dysfunction in the septic patient. Critical Care 2002;6:500-508. 44) Kumar Aseem, Kumar Anand: IL-1 gene cluster polymorphisms: All in the family. Critical Care Medicine 2002;30:1168-1169. 45) Kumar Anand, Kumar Aseem, Parrillo JE: Reversible myocardial depression: A ubiquitous phenomenon in critical illness? Critical Care Medicine 2002;30:1392-1393. 46) Coursin DB, Ketzler, JT, Kumar A, Maki DG. Bioterrorism May Overwhelm Medical Resources. Anesthesia Patient Safety Foundation Newsletter. 2002;17(1):4-8. 47) Kumar A, Darovic G: Catheter related infections. In Handbook of Hemodynamic Monitoring. Editors: Gloria Darovic, R.N. and Corey Franklin, M.D. W.B. Saunders 2003. 48) Darovic G, Kumar A: Monitoring central venous pressure. In Handbook of Hemodynamic Monitoring. Editors: Gloria Darovic, R.N. and Corey Franklin, M.D. W.B. Saunders 2003. 49) Kumar A, Parrillo JE: Myocardial depressant substances in meningococcal septic shock. Critical Care Medicine 2002;30:2379-2380. 50) Kumar Anand, Kumar Aseem: Endotoxemic myocardial depression: A novel iNOS suppressing effect of albumin. Critical Care Medicine 2003;31:324-326. 51) Guest editor: Yearbook of Critical Care Medicine 2003 Editors: RP Dellinger MD, JE Parrillo MD, RA Balk MD, JE Calvin MD, Cory Franklin MD and BA Shapiro MD. Mosby Yearbook Publications 2004. 52) Kumar A, Wood KE, Parrillo JE: Circulating substances and energy metabolism in septic shock. Critical Care Medicine 2003;31:632-633 53) Sharma S, Kumar A: Septic shock, respiratory distress and multiple organ failure. Current Opinion in Pulmonary Medicine. 2003;9:199-209. 54) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2004 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2005

34

55) Wong J, Kumar A: Myocardial depression in sepsis and septic shock. In: Sepsis. Editors: Ortiz-Ruiz G, Perafan MA, Faist E, Castell CD. Springer-Verlag Inc, 2006 56) Ronald J, Balk R, Kumar A: Severe pneumonia in the ICU. In Society of Critical Care Medicine Board Review Manual 2004. Editor: David Porembka. SCCM Publications 2004. 57) Kumar A, Nasraway S: Sepsis and septic shock: Optimizing outcome. In Society of Critical Care Medicine Board Review Manual 2004. Editor: David Porembka. SCCM Publications 2004. 58) Taiberg L, Wong J, Kumar A: Myocardial depression in sepsis and septic shock. Advances in Sepsis 2004;4:82-94 59) Kumar A: Leukocyte lysozyme: A novel cause of septic myocardial depression? Crit Care Med 2004;32:304-305. 60) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2005 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2006 61) Brabant D, Ramana CV, Michael P, Tonnos M, Tessier T, Kung S, Kumar A, Kumar A: Molecular biology of sepsis. Proceedings of the International Biotechnolgy Symposia. Haldia Institute of Technology,India. Jan 15, 2005 62) Anel R, Kumar A. Human endotoxemia and human sepsis: Limits to the model. Critical Care Forum 2005;9:151-152 63) Balk R, Kumar A: Severe pneumonia in the ICU. In Society of Critical Care Medicine Board Review Manual 2005. Editor: David Porembka. SCCM Publications 2005. 64) Kumar A, Nasraway S: Sepsis and septic shock: Optimizing outcome. In Society of Critical Care Medicine Board Review Manual 2005. Editor: David Porembka. SCCM Publications 2005. 65) Kumar A: Pathophysiology of septic shock. SCCM On-line repository 2005 (http://ricu.sccm.org/Security/LectureHome.aspx?LectureID=ee936f0f-d7d7-489b-940e-b3caf9a25bc2) 66) Kumar A: Shock. SCCM On-line repository 2005 (http://ricu.sccm.org/Security/LectureHome.aspx?LectureID=b176837c-259d-472f-8a13-cd4217f4c7a9) 67) Kumar Anand, Kumar Aseem. Nitric oxide and inflammatory cytokines in the heart:

35

The presence of positive feedback loops. Critical Care Med 2005;33:2851-2. 68) Kumar A. Myocardial depression in sepsis and septic shock. Kuwait Medical Journal 2005:37:238-247 69) Kumar A, Parrillo JE: Myocardial Depression in Sepsis and Septic Shock. In 26th International Symposium on Intensive Care and Emergency Medicine, Yearbook of Intensive Care and Emergency Medicine. Editor, JL Vincent. Springer Verlag Publications 2006. 70) Balk R, Kumar A: Severe pneumonia in the ICU. In Society of Critical Care Medicine Board Review Manual 2006. Editor: Michael Ivy. SCCM Publications 2006. 71) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2006 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2007 72) Kumar A. Pathophysiology of Shock. In Anesthesia Science. Editor N Webster. Blackwell Publishing Ltd, Oxford, UK 2007. 73) Balk R, Kumar A: Severe pneumonia in the ICU. In Society of Critical Care Medicine Board Review Manual 2007. Editor: James E. Szalados. SCCM Publications 2007. 74) Kumar A: Implication of early diagnosis of infection on antimicrobial therapy. In Sepsis Handbook: Early Diagnosis of Sepsis. Editors: Phil Dellinger, Jean Carlet. Biomerieux Publications 2007 75) Kumar A, Parrillo JE: Shock: Classification, pathophysiology, and approach to management. In Textbook of Critical Care Medicine. 3

nd Edition. Editors: Joseph E.

Parrillo, MD and R. Phillip Dellinger, MD. Mosby Publications 2007.

76) Kumar Anand, Kumar Aseem, Parrillo JE: Myocardial dysfunction in sepsis and septic shock. In Textbook of Acute Heart Failure Syndromes: A Practical Approach for Physicians. Editors, Alexandre Mebazaa, Mihai Gheorgehiade, Falez Zannad, Joseph Parrillo and Wendy Gattis Stough. Springer-Verlag Ltd 2008. 77) Kumar A: Chapter 15: Infusion-related sepsis. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 4

th Edition. Editor: Gloria Oblouk

Darovic, RN. WB Saunders 2009. 78) Kumar A, Darovic GO: Chapter 8: Establishment of Central Venous Access. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 4

th Edition.

Editor: Gloria Oblouk Darovic, RN. WB Saunders 2009.

36

79) Darovic GO, Kumar A: Chapter 9: Monitoring Central Venous Pressure. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 4

th Edition.

Editor: Gloria Oblouk Darovic, RN. WB Saunders 2009. 80) Darovic GO, Zarychanski R, Kumar A: Chapter 10: Pulmonary Artery Pressure Monitoring. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 4

th Edition. Editor: Gloria Oblouk Darovic, RN. WB Saunders 2009.

81) Dickieson A, Darovic GO, Kumar A: Chapter 11: Monitoring Cardiac Output. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 4

th Edition.

Editor: Gloria Oblouk Darovic, RN. WB Saunders 2009. 82) Kumar Anand, Kumar Aseem: Development of sepsis therapeutics and molecular diagnostics. Expert Commentary Nova Publishing 2008. 83) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2007 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2008 84) Kumar Anand, Kumar Aseem: Sepsis and Septic Shock. In Civetta, Taylor and Kirby’s Critical Care. 4

th Ed. Editors, A Gabrielli, Layon J, Yu M. Lippincott, Williams

and Wilkin Co. 2008 85) Kumar A: Myocardial depression in sepsis and septic shock. Recent Advances in Biochemical and Biophysical Research, Editors: R. Chilakamarti, A. Kumar and R. Enelow, publisher: Research Signpost 2008. 86) Sharma S, Kumar A: Antimicrobial Management of Serious Infections. Guest Editor, Michell Levy, MD. Pulmonary Clinics of North America 2008;29(4):677-687. 87) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2008 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2009 88) Balk R, Kumar A: Severe pneumonia in the ICU. In Society of Critical Care Medicine Board Review Manual 2008. Editor: James E. Szalados. SCCM Publications 2008. 89) Kumar A: Antimicrobial management of sepsis and septic shock. In Society of Critical Care Medicine Refresher Course Manual 2008. Editor: Christina Rehm. SCCM Publications 2008. 90) Kumar A, Parrillo, JE: Preface. Historical Aspects of Critical Care Medicine and Critical Illness. Critical Care Clinics 2009;25(1): xii-xiv 91) Manji R, Wood KE, Kumar A: Evolution and History of Circulatory Shock. Critical Care Clinics 2009;25(1):1-29

37

92) Funk K, Parrillo JE, Kumar A: History of Septic Shock. Critical Care Clinics 2009;25(1):83-101 93) Funk D, Sebat F, Kumar A: A Systems Approach to the Early Recognition and Rapid Administration of Best Practice Therapy in Sepsis and Septic Shock. Current Opinion in Critical Care. 2009;15:301-307 94) Kumar A: Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Critical Care Clinics 2009; 25:733-752 95) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2009 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2010 96) Kumar A: Antimicrobial Therapy in Sepsis and Life-threatening Infection. In Society of Critical Care Medicine Board Review Manual 2009. Editor: Christina Rehm. SCCM Publications 2009. 97) Kumar A: Infections in the Immunosuppressed. In Society of Critical Care Medicine Board Review Manual 2009. Editor: Christina Rehm. SCCM Publications 2009. 98) Kumar A: Multiresistant Infections in the ICU. In Society of Critical Care Medicine Board Review Manual 2009. Editor: Christina Rehm. SCCM Publications 2009. 99) Zarychanski R, Kumar A. Early intravenous unfractioned heparin-also beneficial in acute lung injury? Response to letter. Crit Care Med 2009;37:1534 100) Gin A, Kumar A, Zarychanski R, Honcharik N. Increased sedative use in H1N1 patients in ICU. CMAJ 2009;181(8):500 101) The InFACT Global H1N1 Collaborative. InFACT: a global critical care research response to H1N1. Lancet November 10, 2009 DOI:10.1016/S0140-6736(09)61792-X 102) Clinical Guidance for the Management of Influenza-Like Illness in the Context of Pandemic H1N1 Influenza Virus in Adult Intensive Care Units. http://www.canadiancriticalcare.org/ICU_Guidelines_English.pdf. Public Health Agency of Canada. 2009 103) Ramsey CR, Miller RR, Funk D, Kumar A. Ventilator management for hypoxemic respiratory failure attributable to H1N1 novel swine origin influenza virus. Kumar A, Farmer C. Guest Editors. H1N1 Novel Influenza: Pandemic Issues for Critical Care Practitioners. Critical Care Medicine 2010;38(4):e58-e65. doi:10.1097/CCM.0b013e3181cde600

http://www.canadiancriticalcare.org/ICU_Guidelines_English.pdf

http://journals.lww.com/ccmjournal/Abstract/2010/04001/Ventilator_management_for_hypoxemic_respiratory.8.aspx

http://journals.lww.com/ccmjournal/Abstract/2010/04001/Ventilator_management_for_hypoxemic_respiratory.8.aspx

38

104) Funk D, Siddiqui F, Wiebe K, Miller RR, Bautista E, Jimenez E, Webster K, Kumar A. Practical lessons from the first outbreaks: Clinical presentation, obstacles, and management strategies for severe pandemic (H1N1) 2009 influenza pneumonitis. Kumar A, Farmer C. Guest Editors. H1N1 Novel Influenza: Pandemic Issues for Critical Care Practitioners. Critical Care Medicine 2010;38(4):e30-e37.doi: 10.1097/CCM.0b013e3181d10522 105) Fowler R, Jouvet P, Christian M, Kumar A. Critical illness due to influenza A 2009 H1N1. Critical Care Rounds. Oct 2009 106) Funk D, Zubert S, Kumar A. Antibiotics in sepsis and septic shock: Like everything else in life, timing is everything. Critical Care Medicine 2009:38:1211-1212. 107) Manji RA, Kumar A. Determining relevant cortisol concentrations in critically ill patients. Critical Care 2010:14:113 108) Ramsey C, Fowler R, Kumar A. Mechanical ventilation in critically ill patients with 2009 influenza A(H1N1)—Reply. JAMA 2010:303;940 109) The Writing Committee of the World Health Organization (WHO) Consultation on Clinical Aspects of Pandemic Influenza (H1N1) 2009. Clinical aspects of pandemic influenza A (H1N1) 2009. N Engl J Med 2010:362:1708-1719. 110) Opal S, Kumar A. Influenza. Textbook of Critical Care (6

th ed) Fink MP, Abraham

E, Vincent J-L, Kochanek PM Philadelphia, PA: Elsevier Saunders 2011

111) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2010 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2011 112) Kumar A. Early antimicrobial therapy in severe sepsis and septic shock. Current Infectious Diseases Reports 2010; 12:336–44. 113) Funk D, Kethireddy S, Kumar A. Improving outcomes in sepsis and septic shock: Getting it right the first time. In Sepsis Management: PIRO and MODS. Editors: Rello J, Lipman J, Lisboa T. Springer-Verlag 2010. 114) Kumar A, Safdar N, Kethireddy S, Chateau D. Odds ratios are contingent on event rates-Reply. Crit Care Med 2010; 38; 2426-27. 115) Kumar A and the CATSS Database Group. Mono- or combination- antibiotic therapy for septic shock? An epistemological dilemma-Reply. Crit Care Med 2010;39:423-4. 116) Ramsey C, Kumar A. H1N1: Viral pneumonia as a cause of acute respiratory distress syndrome. Current Opinion in Critical Care 2011: 17:64–71.

39

117) Kumar A. Preface. Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Critical Care Clinics 2011:27:xi-xii. 118) Funk D, Kumar A. Antimicrobial therapy for life-threatening infections: Speed is life. Critical Care Clinics 2011:27: 53-76. 119) Abad CL, Kumar A, Safdar N. Antimicrobial therapy of sepsis and septic shock: When are two drugs better than one? Critical Care Clinics 2011;27 (on-line only). 120) Kumar A. A) One size fits all & never change a winning team? –the need for balanced strategies in antibiotic therapy B) Combination therapy for septic shock--considerations for antibiotic stewardship. C) Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis- Reply. Crit Care Med 2011; 39:609. 121) Rahman O, Kumar A. Case study of pandemic H1N1 infection. Preparing Your ICU for an Effective Disaster Response. Editors, Wax R, Farmer C. SCCM Publications 2011 122) Kumar A, Jouvet P, Christian M, Fowler R. Pandemic H1N1 influenza. Current Concepts in Critical Care 2011. SCCM Publications 2011. 123) Anel R, Kumar A. Bacteremia, sepsis and septic shock. In Enfermedades Infecciosas (Infectious Diseases). Editors: Vesga O, Velez LA, Leiderman E, Restrepo A. Corporación para Investigaciones Biológicas (CIB)'s Editorial Fund 2011 124) Kumar A. Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): Speed is life. J Antimicrob Chemo 2011; 66:959-63. 125) Kumar A. Optimizing antimicrobial therapy in sepsis and septic shock. Critical Care Nursing Clinics of North America 2011;23:79-97 126) Kumar A. A potential selection bias in the study of early combination antibiotic therapy versus monotherapy in septic shock: Reply. Crit Care Med 2011;39;1604-5 127) Patel GP, Kumar A. Antibiotics, antifungal and antivirals. Adult Comprehensive Critical Care Review Textbook 2011. Editor: Mathew Ferris, MD. SCCM Publications. 128) Kumar A. Pandemic H1N1 influenza. J Thorac Dis 2011;3:262-270. DOI: 10.3978/j.issn.2072-1439.2011.08.05 129) Kumar A, Maki D: Donor infection issues. In Management of the Potential Organ Donor Initiative. Editor: Kenneth E. Wood, DO. United States Health and Human Services 2013 (in press)

http://www.sciencedirect.com.proxy1.lib.umanitoba.ca/science?_ob=ArticleURL&_udi=B7RMB-51N0NFJ-8&_user=1068138&_coverDate=01%2F31%2F2011&_rdoc=8&_fmt=high&_orig=browse&_origin=browse&_zone=rslt_list_item&_srch=doc-info%28%23toc%2325746%232011%23999729998%232754736%23FLA%23display%23Volume%29&_cdi=25746&_sort=d&_docanchor=&_ct=15&_acct=C000051258&_version=1&_urlVersion=0&_userid=1068138&md5=bebed2d9248d08d84f3736699a358815&searchtype=a

http://www.sciencedirect.com.proxy1.lib.umanitoba.ca/science?_ob=ArticleURL&_udi=B7RMB-51N0NFJ-8&_user=1068138&_coverDate=01%2F31%2F2011&_rdoc=8&_fmt=high&_orig=browse&_origin=browse&_zone=rslt_list_item&_srch=doc-info%28%23toc%2325746%232011%23999729998%232754736%23FLA%23display%23Volume%29&_cdi=25746&_sort=d&_docanchor=&_ct=15&_acct=C000051258&_version=1&_urlVersion=0&_userid=1068138&md5=bebed2d9248d08d84f3736699a358815&searchtype=a

40

130) Kumar. Preface. Shock: Identification and Treatment. Editor: Rita Galeiras. A Coruña Hospital Complex. Galicia Healthcare Region (Spain) 2012 131) Kethireddy S, Kumar A. Infections in the immunosuppressed and immunocompromised. Comprehensive Critical Care Review: Adult. Editors, Pamela Roberts and S.R. Todd. SCCM Publications 2012 132) Kethireddy S, Kumar A. Antimicrobial De-escalation: Ehrlich’s Mandate Revisited. Current Concepts in Adult Critical Care. Editor, Eugene Cheng. SCCM Publications 2012. 133) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2011 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2012 134) Bleiblo F, Michael P, Brabant D, Ramana CV, Tai TC, Saleh M, Parrillo JE, Kumar Anand, Kumar Aseem. The Role of Immunostimulatory Nucleic Acids in Septic Shock. International Journal of Clinical and Experimental Medicine 2012;5(1):1-23. 135) Michael P, Bleiblo F, Kumar Anand, Kumar Aseem. Not only a toll for viruses: the role of toll-like receptor 3 in nonviral sepsis-induced cardiac depression. Crit Care Med 2012;40:2514-2515 136) Kethireddy S, Kumar A. Mortality due to septic shock following early, appropriate antibiotic therapy: Can we do better? Crit Care Med 2012:40;2228-2229 137) Funk D, Jacobsohn E, Kumar A. The role of the venous return in critical illness and shock. Part I: Physiology. Critical Care Medicine 2013:41;255-262 138) Funk D, Jacobsohn E, Kumar A. The role of the venous return in critical illness and shock. Part II: Shock and mechanical ventilation. Critical Care Medicine 2013:41; 573-579 139) Funk D, Kumar A. If the central venous Pressure Is [x], call me … maybe. Critical Care Medicine 2013;41:1823-1824. 140) Kumar A, Unligil U, Parrillo JE: Shock: Classification, pathophysiology, and approach to management. In Textbook of Critical Care Medicine. 4

th Edition. Editors:

Joseph E. Parrillo, MD and R. Phillip Dellinger, MD. Mosby Publications 2013. 141) Kethireddy S, Kumar A. Trending the fever curve. What does it tell us? Critical Care Medicine 2013;41:2034-2036 142) Rimmer E, Kumar A, Zarychanski R. Effectiveness of Human Recombinant Activated Protein C for Severe Sepsis and Septic Shock in Adult and Pediatric

41

Patients: Randomized Clinical Trial Versus Nonrandomized Study. Reply by authors to letter. Crit Care Med 2013;41:e139-40 143) Ramsey C, Kumar A. Influenza and endemic viral pneumonia. Critical Care Clinics 2013;29:1069–1086 144) Kethireddy S, Darovic G, Kumar A. Catheter-related infections and sepsis. Crit Care Clinics 2013;29:989–1015. 145) Kumar A. An alternate pathophysiologic paradigm of sepsis and septic shock: Implications for optimizing antimicrobial therapy. Virulence 2014;5:80–97 146) Michael P, Brabant D, Bleiblo F, Ramana CV, Rutherford M, Tai TC, Kumar A, Kumar A. Influenza A-induced cellular signal transduction pathways. J Thoracic Dis 2013; 5(Suppl 2): S132–S141. 147) Kumar A: Preface. Life-threatening Infections I. Critical Care Clinics 2013;29(2): xiii-xiv 148) Leligdowicz A, Dodek PM, Norena M, Wong H, Kumar Aseem, Kumar Anand Trends in infection source and mortality among patients with septic shock. Response to letter Am J Resp Crit Care 2014;190:710. 149) Kumar A: Antimicrobial delay and outcome in severe sepsis. Letter re: Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: Results from a guideline-based performance improvement program. Critical Care Medicine 2014;42:e802 150) Liang S, Kumar A. Optimizing antimicrobial therapy in the ICU (3

rd Ed). In

Handbook of ICU Therapy. Eds Fuller J, Granton J, McConachie. Cambridge University Press 2014. London, England. 151) Funk D, Kumar A. Ebola Virus Disease: Update for Anesthesiologists. Canadian Journal of Anesthesia 2015;62:80-91 152) Vasquez-Grande G, Kumar A: Optimizing antimicrobial therapy of sepsis and septic shock: Focus on antibiotic combination therapy. Seminars in Respiratory and Critical Care Medicine 2015;36:154–166. 153) Opal S, Kumar A: Influenza. Textbook of Critical Care (7

th ed) Fink MP, Abraham

E, Vincent J-L, Kochanek PM Philadelphia, PA: Elsevier Saunders 2015

154) Karvellas, C J, Abraldes, JG, Arabi, Y, Kumar, A and the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group (2015),

42

Letter: what else can improve survival in cirrhotic patients with spontaneous bacterial peritonitis and associated septic shock? Authors’ reply. Alimentary Pharmacology & Therapeutics, 2015;42: 123–124. doi: 10.1111/apt.13229

155) Liang S, Kumar A: Empiric antimicrobial therapy in septic shock: Optimizing pathogen clearance. Current Infectious Diseases Reports 2015;17:36 156) Zarychanski R, Kumar A: Letter: What is the best heparin to treat sepsis with? Authors’ reply. Critical Care Medicine 2015:43;e213 157) Cooper J, Kethireddy S, Kumar A. Infections in the Immunosuppressed and Immunocompromised Patient: A Primer for Intensivists. ICU Management 2015;15 (3):112-115 158) Kumar A. Systematic bias in meta-analyses of time to antimicrobial in sepsis studies. Critical Care Medicine 2016:44;234–e235 159) Vasquez-Grande G, Kumar A. Infections in the immunosuppressed and immunocompromised. Comprehensive Critical Care Review: Adult. Editors, Pamela Roberts, S. Rob Todd. SCCM Publications 2016 160) Patel G, Kumar A. Antibiotic, Antifungal, and Antiviral Therapies. Comprehensive Critical Care Review: Adult. Editors, Pamela Roberts, S. Rob Todd. SCCM Publications 2016 161) Sartelli M, Weber DG, Ruppé E, Bassetti M, Wright B, Ansaloni L, et al (includes Anand Kumar). Antimicrobials: A Global Alliance for Optimizing their Rational Use in Intra-Abdominal Infections (AGORA). World J Emergency Surg 2016:11;33 162) Downar J, Delaney JW, Hawryluck L, Kenny L on behalf of the Canadian Critical Care Society’s Withdrawal of Life-Sustaining Treatment Working Group (includes Anand Kumar). Guidelines for the withdrawal of life-sustaining measures. Intensive Care Medicine 2016;42:1003-1017 163) Molnar Z, Giamarellos-Bourboulis E, Nierhaus A, Kumar A. Editorial Comment. Biomed Research International. Special Issue: Sepsis - Diagnostic and Therapeutic Challenges. 2016;1:1-2 164) Roberts J, Kumar A, Lipman J. Right dose, right now: Customized drug dosing in the critically ill. Current Concepts in Adult Critical Care. Editor, Eugene Cheng. SCCM Publications 2017;45:331-336. 165) Vasquez-Grande G, Kumar A: Sepsis and Septic Shock. In Civetta, Taylor and Kirby’s Critical Care. 5

th Ed. Editors, A Gabrielli, Layon J, Yu M. Lippincott, Williams

and Wilkin Co. 2017

43

166) Kumar A, Vasquez-Grande G, Tremblay V, Parrillo JE: Shock: Classification, pathophysiology, and approach to management. In Textbook of Critical Care Medicine. 5

th Edition. Editors: Joseph E. Parrillo, MD and R. Phillip Dellinger, MD. Mosby

Publications 2017. 167) Ful F, Arslantas MK, Cinel I, Kumar A. Changing Definitions of Sepsis. Turkish Journal of Anesthesiology and Reanimation 2017;45:129-136 168) Sartelli M, Labricciosa FM, Barbadoro P, Pagani L, Ansaloni L, Brink AJ et al (includes Kumar A). The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardship—results from an international cross-sectional survey. World J Emerg Surg 2017;12:34

abstracts 1) Feigenbaum A, Kumar A, Weksberg R: Singleton-Merten Syndrome: Autosomal dominant transmission with variable expression. American Journal of Human Genetics 1988;43(3):A48 #190 (suppl) 2) Kumar A, Dimou C, Hollenberg SM, Cunnion RE, Lawrence M, Uretz E, Snell RJ, Parrillo JE: Tumor necrosis factor produces a concentration dependent depression of myocardial cell contraction in-vitro. Clinical Research 1991;39(2):321A 3) Marantz S, Kumar A, Parker S, Alfa M, Kepron W, Lertzman M, Light RB: Quantitative cultures of endotracheal aspirates, bronchoalveolar lavage fluid, and bronchoscopic protected brush specimens in the diagnosis of pneumonia in intubated patients. Clinical and Investigative Medicine 1991;14(4):A22 (suppl) 4) Kumar A, Dimou C, Hollenberg SM, Cunnion RE, Lawrence M, Uretz E, Parrillo JE: Tumor necrosis factor produces depression of myocardial cell contraction in-vitro. Critical Care Medicine 1992;20(4):S52 (suppl) 5) Kumar A, Thota V, Dimou C, Olson J, Uretz E, Parrillo JE: Mechanism of tumor necrosis factor-induced myocardial cell depression in-vitro. Clinical Research 1992;40(2):293A 6) Kumar A, Dimou C, Thota V, Olson J, Uretz E, Parrillo JE: Tumor necrosis factor produces depression of cardiomyocyte shortening in-vitro: Clinical and Investigative Medicine 1992;15(4):A27 #151 (suppl) 7) Kumar A, Thota V, Dimou C, Olson J, Uretz E, Parrillo JE: Mechanism of tumor necrosis factor-induced myocardial cell depression in-vitro. Clinical and Investigative

44

Medicine 1992;15(4):A27 #152 (suppl) 8) Kumar A, Bell D: Intravenous amiodarone for the treatment of rapid atrial fibrillation and flutter in the critically ill. Chest 1992;102(2):128S (suppl) 9) Kumar A, Thota V, Bunnell E, Olson J, Uretz E, Parrillo JE: Effect of inotropes on tumor necrosis factor-induced cardiomyocyte depression in-vitro. Chest 1992;102(2):88S (suppl) 10) Kumar A, Thota V, Olson J, Uretz E, Parrillo JE: Effect of nitric oxide synthetase inhibition on tumor necrosis factor induced myocardial cell depression in-vitro. JACC 1993;21:477A (suppl) 11) Rodriguez ER, Mientus TF, Ariztia EV, Kumar A, Parrillo JE: The inducible form of nitric oxide synthase is up-regulated by endotoxin treatment of cultured rat cardiac myocytes. JACC 1993;21:374A (suppl) 12) Kumar A, Kosuri R, Kandula P, Thota V, Olson J, Dee L, Stolz U, Uretz E, Parrillo JE: Tumor necrosis factor-induced myocardial cell depression in-vitro is mediated by nitric oxide generation. Critical Care Medicine 1993;21:S278 13) Kumar A, Kosuri R, Kandula P, Thota V, Olson J, Uretz E, Parrillo JE: Tumor necrosis factor-induced myocardial cell depression in vitro is not a cyclic AMP dependent process. Clinical Research 1993;41:198A 14) Kumar A, Thota V, Ginsburg B, Dee L, Olson J, Kim J, Uretz E, Parrillo JE: Supernatants of endotoxin stimulated THP-1 cells depress myocardial cell contractility in-vitro. Clinical Research 1993;41:140A 15) Kumar A, Kosuri R, Thota V, Dee L, Olson J, Uretz E, Parrillo JE: Effect of nitric oxide synthetase inhibition on human septic serum-induced myocardial cell depression in-vitro. Circulatory Shock 1993;Suppl 2:22 #62 16) Kumar A, Kosuri R, Kandula P, Thota V, Olson J, Uretz E, Parrillo JE: Tumor necrosis factor-induced cardiomyocyte depression is not a cyclic AMP dependent process. Clinical and Investigative Medicine 1993;16:B42 #256 17) Kumar A, Kosuri R, Thota V, Dee L, Olson J, Uretz E, Parrillo JE: Nitric oxide and cyclic GMP generation mediates human septic serum-induced in-vitro cardiomyocyte depression. Chest 1993;103(2):12S (suppl) 18) Kumar A, Kosuri R, Thota V, Olson J, Dee L, Stolz U, Uretz E, Parrillo JE: Tumor necrosis factor-induced myocardial cell depression is mediated by nitric oxide and cyclic GMP generation. Circulation 1993;88:I617 #3320 (suppl)

45

19) Kumar A, Kosuri R, Ginsburg B, Dee L, Kim J, Olson J, Uretz E, Casey L, Parrillo JE: Myocardial cell contractility is depressed by supernatants of endotoxin stimulated THP-1 cells. Critical Care Medicine 1994;22:A118 20) Kumar A, Kosuri R, Dee L, Olson J, Uretz E, Parrillo JE: Selective immunoabsorption of IL-1 and TNF abrogates the in-vitro cardiomyocyte depressant effect of human septic serum. Critical Care Medicine 1994;22:A118 21) Kumar A, Kosuri R, Kandula P, Kandula P, Olson J, Dee L, Olson J, Uretz E, Parrillo JE: Tumor necrosis factor-induced myocardial cell depression is mediated by nitric oxide and cyclic GMP generation. Critical Care Medicine 1994;22:A191 22) Kumar A, Kosuri R, Kandula P, Olson J, Uretz E, Parrillo JE: Cardiomyocyte depression induced by human septic serum is mediated by nitric oxide and cyclic GMP generation. Critical Care Medicine 1994;22:A119 23) Schupp E, Kumar A, Bunnell E, Uretz E, Calvin J, Ali A, Parrillo JE: The cardiovascular response to incremental doses of dobutamine in septic shock: Mechanism of hemodynamic response. Critical Care Medicine 1994;22:A109 24) Schupp E, Kumar A, Bunnell E, Uretz E, Calvin J, Ali A, Parrillo JE: The cardiovascular response to incremental doses of dobutamine in septic shock: Prediction of survival. Critical Care Medicine 1994;22:A109 25) Kumar A, Kosuri R, Kandula P, Lakshminarayanan L, Bunnell, Dee L, Olson J,

Uretz E, Parrillo JE: Interleukin-1 but not endotoxin, interferon-, or interleukin-6 depresses myocardial cell contractility in-vitro. Clinical Research 1994;42:168A 26) Kumar A, Kosuri R, Kandula P, Lakshminarayanan L, Dee L, Olson J, Uretz E, Parrillo JE: Human septic serum-induced in-vitro cardiomyocyte depression is caused

by the synergistic action of TNF- and IL-1. Clinical Research 1994;42:168A 27) Kumar A, Schupp E, Bunnell E, Uretz E, Calvin J, Ali A, Parrillo JE: Cardiovascular response to dobutamine in septic shock. Clinical and Investigative Medicine 1994;17:B18 #107 28) Kumar A, Dee L, Olson J, Uretz E, Parrillo JE: Human septic serum induced

cardiomyocyte depression is caused by the synergistic action of TNF- and IL-1. Clinical and Investigative Medicine 1994;17:B19 #115

29) Kumar A, Kosuri R, Kandula P, Olson J, Dee L, Uretz E, Parrillo JE: Interleukin-1-induced myocardial cell depression is mediated by nitric oxide and cyclic GMP generation. Critical Care Medicine 1995;23:A149 30) Kumar A, Kandula P, Lakshminarayanan L, Dee L, Olson J, Uretz E, Parrillo JE. IL-

46

1 but not endotoxin, IL-2, IL-4, IL-6, IL-8, IL-10, or interferon- depresses myocardial cell contractility in-vitro. Critical Care Medicine 1995;23:A168 31) Kumar A, Kosuri R, Kandula P, Dee L, Olson J, Uretz E, Parrillo JE. Human septic serum induces depression of cardiac myocyte contraction through the synergistic

actions of TNF- and IL-1. Critical Care Medicine 1995;23:A262 32) Kumar A, Thota V, Kosuri R, Kandula P, Olson J, Dee L, Uretz E, Parrillo JE: Tumor necrosis factor impairs epinephrine-stimulated cardiomyocyte contractility and cyclic AMP response. Critical Care Medicine 1995;23:A148 33) Goldfarb R, Guynn T, Kumar A, Trenholme G, Parrillo JE: Cardiovascular abnormalities of human sepsis modeled in the pig. Crit Care Med 1995;23:A150 34) Sun Y, Kumar A, Hollenberg SM, Porter E, Parrillo JE: Transforming growth factor inhibits tumor necrosis factor-induced depression of cardiac myocyte contractility. Journal of Investigative Medicine (Clinical Research) 1995;43;480A 35) Sun Y, Brar R, Kumar A, Hollenberg SM, Parrillo JE. Effects of nitric oxide synthase (NOS) inhibition on tumor necrosis factor-induced depression of cardiac myocytes in-vitro. J Invest Med 1996;44:447A 36) Brar R, Kumar A, Schaer GL, Hollenberg S, Hursey T, Sun Y, Parrillo JE: Myocardial infarction and reperfusion produces soluble myocardial depressant activity that correlates with infarct size. Crit Care Med 1996;24:A30

37) Kumar A, Brar R, Sun E, Olson J, Parrillo JE: Tumor necrosis factor- (TNF) impairs isoproterenol-stimulated cardiac myocyte contractility and cyclic AMP production via a nitric oxide-independent mechanism. Crit Care Med 1996;24:A95 38) Kumar A, Sun E, Parrillo JE: Endotoxin does not contribute to cardiac myocyte

depression produced by TNF, IL-1, or human septic serum. Crit Care Med 1996;24:A95 39) Brar R, Kumar A, Schaer G, Hollenberg S, Hursey T, Sun Y, Parrillo J: Release of soluble myocardial depressant activity by reperfused myocardium. JACC 1996;27:386A. 40) Kumar A, Kosuri R, Dee L, Allen J, Parrillo JE: Divergent effects of epinephrine and amrinone on contractility and cyclic AMP generation of TNF-exposed cardiac myocytes. Crit Care Med 1997;25:A114. 41) Kumar A, Anand A, Krottapalli H, Alahdab K, Wang P, Skorupa G, Hollenberg S,

Parrillo JE: Transforming growth factor (TGG)- inhibits TNF and IL-1-induced depression of cardiac myocyte contractility. Critical Care Medicine 1998;26:A39.

47

42) Kumar A, Alahdab K, Anand A, Krottapalli H, Wang P, Skorupa G, Khadour F, Schulz R, Parrillo JE: Early depression of cardiac myocyte contractility induced by a

synergistic combination of TNF and IL-1 is mediated by constitutive nitric oxide (NO) synthetase and cyclic GMP (cGMP). Crit Care Med 1998;26:A34. 43) Kumar A, Kumar A, Parrillo JE: Characterization of intracellular signaling components involved in sepsis. European Cytokine Network 1998;9(3):356 44) Symeonides S, Kumar Anand, Trenholme G, Kumar Aseem, Prasad B, Saleem M, Narang P, Avula S, Aboul-Saoud A, Lingam D, Skorupa G, Matuschek M, Parrillo JE: A new murine model of E. coli peritonitis and septic shock. Program and Abstracts 36

th

Annual meeting of the Infectious Diseases Society of America 1998 abstract #190 page 111 45) Rozynek M, Parmar M, Paladugu B, Pellekonda V, Malik V, Krottapalli H, Yenigalla Y, Kumar Aseem, Parrillo JE, Kumar Anand. Tumor necrosis factorα (TNFα) impairs catecholamine-stimulated myocyte contractility via both nitric oxide-dependent and independent mechanisms. J Invest Med 1998;46:253A 46) Prasad B, Rozynek M, Zarzycka E, Saleem M, Taiberg L, Kumar Aseem, Symeoneides S, Matuschek M, Skorupa G, Trenholme G, Parrillo JE, Kumar Anand. A new murine model of E. coli peritonitis and septic shock. J Invest Med 1998;46:257A 47) Kumar Aseem, Kumar Anand, Symeonides S, Skorupa G, Paladuga B, Lingam D, Saleem A, Avula A, Sindha K, Aboul-Saoud A, Surapaneni K, Narang P, Parvathala P, Vukonich M, Goldfarb R, Parrillo JE. Characterization of intracellular signalling components involved in sepsis. Crit Care Med 1999;27:A58 48) Kumar Anand, Kumar Aseem, Choudhury E, Saleem M, Avula S, Parvathala P, Aboul-Saoud A, Surapaneni K, Lingam D, Prasad B, Skorupa G, Parrillo JE.

Transforming growth factor (TGF)- inhibits human septic serum-induced depression of cardiac myocyte contractility. Crit Care Med 1999;27:A124 49) Symeoneides S, Kumar Aseem, Prasad B, Saleem M, Narang P, Avula S, Aboul-Saoud A, Lingam D, Skorupa G, Matuschek M, Goldfarb R, Trenholme G, Parrillo JE and Kumar Anand. A novel murine model of E. coli peritonitis simulates human septic shock. Crit Care Med 1999;27:A127 50) Kumar Anand, Symeoneides S, Kumar Aseem, Prasad B, Saleem M, Avula S, Makkena R, Battula R, Lingam D, Sindha K, Skorupa G, Matuschek M, Goldfarb R, Trenholme G and Parrillo JE. A novel murine model of E. coli peritonitis simulates human septic shock. Journal of Investigative Medicine 1999;47:197A.

48

51) Kumar Aseem, Kumar Anand, Vukonich M, Skorupa G, Symoneides S, Prasad B, Lingam D, Saleem A, Avula S, Sindha K, Parvathala P, Makkena R, Battula R and Parrillo JE. Transcription factor activation in myocardial tissue exposed to human septic serum. Journal of Investigative Medicine 1999;47:197A. 52) Kumar Aseem, Kumar Anand, Vukonich M, Skorupa G, Paladugu B, Saleem M, Narang P, Battula R, Sindha K, Lingam D, Parvathala P, Avula S, Aboul-Saoud A, Merchant H, Makkena R, Haery C and Parrillo JE: Characterization of intracellular signalling components involved in sepsis. The Miami 1999 Nature Biotechnology Winter Symposium. Miami nature Biotechnology Short Reports, Volume 10: Advances in Gene Technology; Signal transduction and therapeutic strategies, 1999;10:74 53) Kumar Anand, Kumar Aseem, Skorupa G, Vukonich M, Paladugu B, Saleem A, Narang P, Avula S, Parvathala P, Lingam D, Sindha K, Battula R, Makkena R, Haery C and Parrillo, JE. Early human septic serum-induced cardiac myocyte depression is caused by synergistic stimulation of a constitutive nitric oxide synthase

by TNF and IL-1. The Miami 1999 Nature Biotechnology Winter Symposium. Miami nature Biotechnology Short Reports, Volume 10: Advances in Gene Technology; Signal transduction and therapeutic strategies, 1999;10:39 54) Haery C, Symeoneides S, Kumar Aseem, Prasad B, Skorupa M, Vukonich M, Goldfarb R, Trenholme G, Parrillo JE, Kumar Anand. A novel murine model of E. coli sepsis. Chest 1999:116;288S. 55) Kumar Aseem, Kumar Anand, Vukonich M, Haery C, Parrillo JE. Characterization of the JAK/STAT pathway during sepsis. Crit Care Med 1999;27:262. 56) Kumar Aseem, Kumar Anand, Parrillo JE. Identification of gene expression patterns during sepsis utilizing DNA gene arrays. Crit Care Med 1999;27:263. 57) Pahwa R, Anel R, Alahdab MT, Alahdab MK, Schupp E, Sun F, Ali A, Parrillo JE, Kumar Anand. Cardiovascular response to dobutamine in septic shock. Crit Care Med 1999;27:384. 58) Anel R, Paladugu B, Makkena R, Haery C, Ganga H, Skorupa G, Vukonich M,

Kumar Aseem, Parrillo JE, Kumar Anand. TNF induces a proximal defect of -adrenoreceptor signal transduction in cardiac myocytes. Crit Care Med 1999;27:248. 59) Jindal N, Paladugu B, Haery C, Makkena R, Patel D, Adoni N, Patel V, Vukonich M, Trenholme G, Kumar Aseem, Parrillo JE, Kumar Anand. Antibiotics and fluid resuscitation in a murine model of septic shock. Crit Care Med 1999;27:269. 60) Landgarten M, Paladugu B, Makkena R, Haery C, Patel D, Adoni N, Vukonich

49

M, Skorupa G, Trenholme G, Kumar Aseem, Parrillo JE, Kumar Anand. Timing of steroid administration in septic shock. Crit Care Med 1999;27:265. 61) Anel RL, Schupp E, Marshall S, Parrillo JE, Kumar A. Cardiovascular response to dobutamine infusion in human septic shock. Crit Care Med 2000;28:617. 62) Anel RL, Bunnell G, Habet K, Neumann A, Parrillo JE, Kumar A. Normal saline increases ejection fraction in normal volunteers. Crit Care Med 2000;28:166. 63) Zanotti S, Bunnell G, Parrillo JE, Habet K, Neumann A, Anel R, Toya S, Cutler D, Kumar A: Interleukin-10 administrations blunts the pro-inflammatory cytokine response to endotoxin challenge in healthy volunteers. Crit Care Med 2001;29:55 64) Osman J, Paladugu B, Parrillo JE, Taiberg L, Haery C, Kumar Aseem, Kassas E,

Kakadia H, Goldfarb R, Kumar Anand: Tranforming growth factor-1 decreases mortality during murine endotoxic shock. Crit Care Med 2001;29:137/S28 65) Osman J, Taiberg L, Paladugu B, Kumar Aseem, Goldfarb R, Parrillo JE, Kumar Anand. Myocardial depression measured with a micro-conductance catheter in a murine model of endotoxic shock. Crit Care Med 2002:30:A70 66) Taiberg L, Osman J, Paladugu B, Kumar Aseem, Goldfarb R, Parrillo JE, Kumar

Anand. Transforming growth factor-1 blocks endotoxin-induced myocardial depression in mice. Crit Care Med 2002;30:A55 67) Osman J, Parrillo JE, Kumar A. Improved survival in a murine model of endotoxin-induced shock by transforming growth factor-β1. Clinical and Experimental Pharmacology and Physiology 2002;29:A90. 68) Jilkina O, Kuzio B, Kumar A, Kupriyanov VV. Effects of Profinflammatory cytokines released during sepsis and septic shock on cardiac energetics, mitochondrial K+ transport and oxygenation. Exp Clin Cardiol 2004;9(1):58 69) Roberts D, Kumar A, Sharma S. Time to appropriate antibiotic administration is a critical determinant of outcome in pneumonia-associated septic shock. Chest 2004 2004;126:724S 70) Kumar A, Mensing J, Zelenitsky S, Ariano R, Parrillo JE. Effect of antibiotic sequence on blood bacterial counts in a rat model of E. coli peritonitis/septic shock. Interscience Conference on Antimicrobial Agents and Chemotherapy 2004, A-1296 page 26. 71) Kumar A, Wood K, Gurka D, Feinstein D, Roberts D. Duration of hypotension prior to antimicrobial administration is a critical determinant of outcome in human septic

50

shock. Interscience Conference on Antimicrobial Agents and Chemotherapy 2004, K-415, page 326. 72) Kumar A, Wood K, Gurka D, Feinstein D, Roberts D. Outcome of septic shock correlates with duration of hypotension prior to source control implementation. Interscience Conference on Antimicrobial Agents and Chemotherapy 2004, K1222, page 350. 73) Kumar A, Mensing J, Haery C, Paladugu B, Taiberg L, Osman J, Parrillo JE. Duration of hypotension prior to antibiotic administration is a critical determinant of outcome in a murine model of E. coli septic shock. Interscience Conference on Antimicrobial Agents and Chemotherapy 2004, A-1861, page 36. 74) Ronald J, Suppes R, Gulati H, Halmarson E, Selaman M, Dellinger P, Kramer A, Roberts D, Kumar A. Effect of timing of antimicrobial administration on mortality in septic shock patients. The Toronto Critical Care Medicine Symposium 2004 75) Ronald J, Suppes R, Gulati H, Halmarson E, Selaman M, Dellinger P, Kramer A, Roberts D, Kumar A. Survival from septic shock correlates with duration of hypotension prior to source control implementation. The Toronto Critical Care Medicine Symposium 2004 76) Kumar A, Kazmi M, Roberts D, Wood K, Taiberg L, Feinstein D, Gurka D, Ronald J, Sharma S, Kramer A, Suppes R, Parrillo JE. Duration of shock prior to antimicrobial administration is the critical determinant of survival in human septic shock. Crit Care Med 2004:32 (12 suppl): #41 page 11. 77) Kumar A, Kazmi M, Ronald J, Seleman M, Roberts D, Gurka D, Wood K, Suppes R, Feinstein D, Zanotti S, Parrillo J, Dellinger P. Rapidity of source control implementation following onset of hypotension is a major determinant of survival in human septic shock. Crit Care Med 2004:32(12 suppl): #564 page 160. 78) Kumar A, Kumar A, Paladugu B, Mensing J, Haery C, Symeoneides S, Goldfarb R, Parrillo JE. Duration of hypotension prior to antibiotic therapy is a critical determinant of survival in a murine model of E. coli septic shock. Crit Care Med 2004:32 (12 suppl): #507 page 143. 79) Pakhale S, Roberts D, Light R, Sharma S, Kumar A. A geographically and temporally comprehensive analysis of septic shock: Impact of age, sex and socioeconomic status. The Toronto Critical Care Medicine Symposium 2005. 80) Zarychanski R, Gulati H, Roberts D, Sharma S, Houston DS, Kumar A. Systemically administered heparin is associated with increased survival in patients diagnosed with septic shock. The Toronto Critical Care Medicine Symposium 2005. Can J Anesthesia 2006;53:418-419

51

81) Nahra R, Mankad A, Zanotti S, Kumar A. Mycobacterium Tuberculosis: An unusual yet highly fatal cause of septic shock. Chest 2005;128:380S 82) Shanaah A, Zanotti S, Parrillo S, Taiberg L, Feinstein D, Suppes R, Roberts D, Kumar A. Impact of body mass index on mortality in patients with septic shock. Critical Care Medicine 2005;33:A164 83) Pakhale S, Roberts D, Light R, Sharma S, Kumar A. A geographically and temporally comprehensive analysis of septic shock: Impact of age, sex and socioeconomic status. Critical Care Medicine 2005;33:A79. 84) Brabant D, Michael P, Tonnos M, Tessier M, Kung S, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Identification and characterization of mediators of sepsis. ACFAS, Montreal, Canada. March 2006. 85) Al-Shirawi N, Arabi Y, Kumar A, Kim C, Li J, Jaswal D, Gonzales C, Serrano R, Delgra S, Al-Shimemeri A, Memish Z. Impact of antibiotic timing outcome of cirrhotic patients admitted to the ICU with septic shock. Proceeding of the American Thoracic Society 2006 Conference. San Diego, CA USA, #A500 86) Tessier M, Tonnos M, Michael P, Brabant D, Kung S, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Characterization of signaling pathways that occur during sepsis. Northern Research Conference, Northern Ontario School of Medicine and Algoma University, Sault St. Marie, Ontario, Canada. June 2006. 87) Kung S, Michael P, Tonnos M, Brabant D, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. The role that bacterial RNA plays in mediating myocyte contraction depression. Northern Research Conference, Northern Ontario School of Medicine and Algoma University, Sault St. Marie, Ontario, Canada. June 2006. 88) Brabant D, Michael P, Tonnos M, Tessier M, Kung S, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Sepsis mediated cellular dysfunction is mediated by DFF 40-induced apoptosis. NOSM Lakehead Research Conference. June 2006. 89) Brabant D, Michael P, Tonnos M, Tessier M, Kung S, Kirwan T, Omri A, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Human septic sera induces death receptor-mediated apoptosis in human fibroblasts. Canadian Federation of Biological Sciences, Ottawa, ON, October 2006. 90) Kirwan T, Brabant D, Michael P, Tessier M, Tonnos M, Kung S, Omri A, Ramana CV, Kumar Anand, Parillo JE and Kumar Aseem. Characterization of intracellular signaling components involved in sepsis. Canadian Federation of Biological Sciences, Ottawa, ON, October 2006.

52

91) Kung S, Michael P, Tonnos M, Tessier M, Brabant D, Kirwan T, Kekkonen V, Omri A, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Bacterial RNA and viral RNA-mediated stress-induced apoptosis involves double-stranded RNA Protein Kinase (PKR) pathway. Canadian Federation of Biological Sciences, Ottawa, ON, October 2006. 92) Tonnos M, Tessier M, Michael P, Brabant D, Kung S, Kirwan T, Omri A, Ramana CV, Kota R, Parissenti AM, Parrillo JE, Kumar

Anand and

Kumar Aseem. Characterization

of gene expression profiles that occur during sepsis. Canadian Federation of Biological Sciences, Ottawa, ON, October 2006. 93) Bahador M, Spevetz A, Milcarek B, Parrillo JE, Kumar A. The relationship of presenting body temperature and WBC count of septic shock patients with survival and length of stay in hospital. Crit Care Med 2006;34 (suppl): A103 #377 94) Zarychanski R, Gulati H, Roberts D, Sharma S, Houston DS, Kumar A. Systemically administered heparin is associated with increased survival in patients diagnosed with septic shock. Crit Care Med 2006;34 (suppl): A110 #398 95) Kirwan T, Michael P, Brabant D, Tonnos M, Kung S, Tessier M, Ramana CV, Omri A, Parrillo JE, Kumar Anand and Kumar Aseem. Characterization of transcription factor signaling pathways in sepsis. Northern Research Conference, Northern Ontario School of Medicine and Algoma University, Sault St. Marie, Ontario, Canada. June 2007

96) Brabant D, Michael P, Tonnos M, Kung S, Kirwan T, Tessier M, Omri A, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Characterizing the role that the extrinsic and intrinsic apoptotic pathways play during sepsis. Northern Research Conference, Northern Ontario School of Medicine and Algoma University, Sault St. Marie, Ontario, Canada. June 2007.

97) Kung S, Michael P, Tessier M, Brabant M, Kirwan T, Tonnos M, Omri A, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Late stage sepsis gene expression profiling. Northern Research Conference, Northern Ontario School of Medicine and Algoma University, Sault St. Marie, Ontario, Canada. June 2007. 98) Kumar A, Suppes R, Gulati H, Halmarstrom E, Dodek P. The impact of initiation of inadequate antimicrobial therapy on survival in human septic shock. Interscience Conference on Antimicrobial Agents and Chemotherapy 2007 99) Kumar A, Suppes R, Gulati H, Halmarstrom E, Skrobik Y, Ellis P. The high mortality of Candida septic shock is explained by excessive delays in initiation of antifungal therapy. Interscience Conference on Antimicrobial Agents and Chemotherapy 2007

53

100) Brabant D, Kirwan T, Michael P, Tonnos M, Kung S, Ramana CV, Omri A, Parrillo HE, Kumar A and Kumar A. Characterization of transcription factor signaling pathways in sepsis. International Society for Interferon and Cytokine Research (ISICR) 2007 101) Brabant D, Kirwan T, Michael P, Tonnos M, Kung S, Ramana CV, Omri A, Parrillo HE, Kumar A and Kumar A. Characterization of sepsis induced apoptotic pathways. International Society for Interferon and Cytokine Research (ISICR) 2007 102) McCarthy B, Fu W, Sullivan K, Peters C, Muggaberg S, Kravetsky L, Bohmeier R, Kumar R, Kosick T, Chan C, Ren J, Paulin H, Khan F, Campbell L, Kumar A and the CATSS Database Research Group. Cholecystitis-related septic shock: Impact of rapidity of antimicrobial therapy and source control. Canadian Critical Care Forum 2007 103) Siddiqui F, Chateau D, Galbraith J, Kumar A and the CATSS Database Research Group. Early changes in serum creatinine and vasopressors are associated with mortality in septic shock. Canadian Critical Care Forum 2007 104) Siddiqui F, Woodward B, Wang Y, Kumar A and the CATSS Database Study Group. Cumulative Vasopressor Index (CVI) as an assessment of cardiovascular organ dysfunction and indicator of outcome in patients with septic shock. Canadian Critical Care Forum 2007 105) Siddiqui F, Kumar R, Fu W, Chan C, Ren J, Kosick T, Peters C, Sullivan K, Muggaberg S, Kravetsky L, Bohmeier R, Tchokonte R, Khan F, Campbell L, Paulin H, Kumar A and the CATSS Database Research Group. The high mortality of candida septic shock is explained by excessive delays in initiation of antifungal therapy. Canadian Critical Care Forum 2007 106) Siddiqui F, Kumar R, Khan F, Campbell L, Paulin H, Fu W, Chan C, Ren J, Kosick T, Peters C, Sullivan K, Muggaberg S, Kravetsky L, Bohmeier R, Tchokonte R, Kumar A and the CATSS Database Research Group. Candida septic shock mortality is explained by delays in initiation of antifungal therapy. Critical Care Medicine 2007:35 (suppl); A248 # 892 107) McCarthy B, Sullivan K, Muggaberg S, Kravetsky L, Kumar R, Fu W, Chan C, Ren J, Kosick T, Peters C, Bohmeier R, Tchokonte R, Khan F, Campbell L, Paulin H, Kumar A and the CATSS Database Research Group. The impact of initiation of inadequate antimicrobial therapy on survival in human septic shock. Critical Care Medicine 2007:35 (suppl); A146 #532 108) McCarthy B, Fu W, Sullivan K, Peters C, Muggaberg S, Kravetsky L, Bohmeier R, Kumar R, Kosick T, Chan C, Ren J, Paulin H, Khan F, Campbell L, Kumar A and the CATSS Database Research Group. Cholangitis-related septic shock: Impact of rapidity

54

of antimicrobial therapy and source control. Critical Care Medicine 2007:35 (suppl); A149 #543 109) McCarthy B, Fu W, Sullivan K, Peters C, Muggaberg S, Kravetsky L, Bohmeier R, Kumar R, Kosick T, Chan C, Ren J, Paulin H, Khan F, Campbell L, Kumar A and the CATSS Database Research Group. Cholecystitis-related septic shock: Impact of rapidity of antimicrobial therapy and source control. Critical Care Medicine 2007:35 (suppl); A152 #551 110) Siddiqui F, Chateau D, Kumar A and the CATSS Database Research Group. Early changes in serum creatinine compared to vasopressors and association with septic shock mortality. Critical Care Medicine 2007:35 (suppl); A177 #637 111) Siddiqui F, Woodward B, Wang Y, Kumar A and the CATSS Database Study Group. Cumulative vasopressor index (CVI) as an assessment of cardiovascular organ dysfunction and indicator of outcome in patients with septic shock. Critical Care Medicine 2007:35 (suppl); A7 #28 112) Low R A, Ahsan AH, Chou H, Bahrainian M, Singh A, Kumar A and the CATSS Database Group. Central-line related septic shock: Early appropriate antimicrobial therapy and rapid catheter removal reduce mortality. 28

th International Symposium on

Intensive Care and Emergency Medicine. 2008 Brussels, Belgium. 113) Hussein S, Kung S, Bleiblo F, Michael P, Brabant D, Kirwan T, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Characterization of bacterial RNA- induced signal transduction pathways that cause cellular dysfunction. Northern Health Research Conference, North Bay, Ontario, Canada. May 2008. 114) Kirwan T, Michael P, Brabant D, Bleiblo F, Kung S, Hussein S, DeLongchamp J, Ramana CV, Omri A, Parrillo JE, Kumar Anand and Kumar Aseem. Characterization of the role of STAT, IRF and NF-κB signaling during sepsis. Northern Health Research Conference, North Bay, Ontario, Canada. May 2008. 115) Kirwan T, Michael P, Brabant D, Bleiblo F, Kung S, Hussein S, DeLongchamp J, Ramana CV, Omri A, Parrillo JE, Kumar Anand and Kumar Aseem. Human septic sera induces apoptosis and DNA Fragmentation Factor 40 activation in human fibroblasts. Northern Health Research Conference, North Bay, Ontario, Canada. May 2008. 116) Manji R, Ahsan MW, Kumar A, CATSS Database Research Group. In septic patients with low cardiac index, initial high or low pulmonary capillary wedge pressure Is not useful to determine ICU outcome. Critical Care Med 2009;37:A239. 117) Manji R, Ahsan MW, Kumar A, CATSS Database Research Group. Patients with septic shock and low cardiac index have inadequate septic treatment and have worse outcomes. Critical Care Med 2009;37:A240.

55

118) Zarychanski R, Turgeon AF, Hebert PC, Cook DJ, Tinmouth A, Kumar A et al. The use of anticoagulants in severe sepsis and septic shock: A national survey of critical care physicians. Crit Care Med 37[12 (suppl)], A427. 2009 119) Zubert S, Kumar A, Funk D. Reduction in time to effective antimicrobial therapy and survival in human septic shock in community and teaching hospital emergency departments. Canadian Critical Care Forum 2010 120) Muscedere J, Long J, Ofner M, Kumar A, McGeer A , Marshall J, Jouvet P, Cook C, Fowler R for the ICU-Flu Study Investigators. Prevalent and incident bacterial infections among Canadian critically ill patients with Influenza A(H1N1) 2009. Canadian Critical Care Forum 2010 121) Jung J, Fowler R, Long J, Zarychanski R, Rodin R, Cook D, Jouvet P, Marshall J, Kumar A on behalf of the ICU-Flu Investigators. 2009-2010 H1N1-related critical illness among aboriginal and non-aboriginal Canadians. Canadian Critical Care Forum 2010 122) Delaney J, Fowler R, Long J, Lamontagne F, Marshall J, Kumar A, Cook D, Hutchison J, Jouvet P on behalf of the ICU-Flu Investigators. Corticosteroids in the treatment of Influenza A 2009 (H1N1)-associated critical illness. Canadian Critical Care Forum 2010 123) Beck V, Kumar A and the CATSS Database Research Group. Does delay in vasopressor administration affect mortality in patients with septic shock? Crit Care Medicine 2011. 124) Muscedere J, Long J, Ofner M, Kumar A, McGeer A, Marshall J, Jouvet P, Cook D, Fowler R for the ICU-Flu Study Investigators. Prevalent and incident positive bloodstream and respiratory cultures among Canadian critically ill patients with influenza A (H1N1) 2009-Preliminary data. Am J Resp Crit Care Med 2011;xxxx :xxxx 125) Kho M, McDonald E, Zytaruk N, Tkaczyk A, Fowler R, Christian M, Kumar A, Burns K, Marshall J, Cook D. Clinical research preparation for the H1N1 pandemic. Am J Resp Crit Care Med 2011;18124 :A104 126) Sharma S, Liu E, Sahai B, Kumar A, Summers R. Quantitation of cytokines and chemokines in the lungs of severely ill 2009 H1N1 patients. Am J Respir Crit Care Med 183;2011:A5230 127) Delaney J, Fowler R, Long J, Lamontagne F, Marshall J, Kumar A, Hutchison J, Jouvet J, On behalf of the ICU-Flu Investigators. Corticosteroids in the treatment of Influenza A 2009 (H1N1) - associated critical illness. Am J Resp Crit Care Med 2011; 17678:B49

56

128) Gu S, Long J, Menon K, Cook D, McGeer A, Kumar A, Jouvet P, Marshall J, Hutchison J, Fowler RA On behalf of the ICU-Flu Investigators. A Comparison of the First and Second Waves of H1N1-Related Critical Illness in Canada. Am J Resp Crit Care Med 2011;17711:B49. 129) Jung J, Fowler R, Long J, Zarychanski R, Rodin R, Cook D, Jouvet P, Marshall J, Kumar A, On behalf of the ICU-Flu Investigators. 2009-2010 H1N1-related critical illness among aboriginal and non-aboriginal Canadians. Am J Resp Crit Care Med 2011;16731:B49. 130) Kharma N, Gerstein R, Kumar A, Sharma S.

. Chest radiographic and CT findings

in pandemic influenza A (H1N1) virus infection. Am J Respir Crit Care Med 183;2011:A4920 131) Rimmer E, Kumar A, Houston D, Doucette S, Zarychanski R. Activated protein C and septic shock: A propensity-matched cohort study. International Society of Thrombosis and Hemostasis 2011. 132) Ariano RE, Zelenitsky SA, Kumar A, Baxter M, Adam H, Karlowsky JA, Hoban DJ, Canadian Antimicrobial Resistance Alliance (CARA), Zhanel GG. Antimicrobial resistance in 4105 pathogens from Canadian hospital intensive care units (ICU): CANWARD database 2007-2010. ICAAC 2011. 133) Alkurdi N, Kumar A, Ariano R, Zelenitsky S, Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Investigating ceftobiprole (Cef) alone and in combination with daptomycin (Dap), linezolid (Lin) and vancomycin (Van) against methicillin-resistant Staphylococcus aureus (MRSA) in an in vitro infection model. ICAAC 2011. 134) Sood MM, Rigatto C, Shafer LA, Bueti J, Komenda P, Kumar A for the Cooperative Antimicrobial Therapy in Septic Shock (CATSS) Database Research Group. Reversible AKI is associated with improved survival compared to persistent or no AKI in septic shock. American Society for Nephrology 2012 135) Mandelzweig K, Sood MM, Rigatto C, Komenda K, Bueti J, Kumar A for the Cooperative Antimicrobial Therapy in Septic Shock (CATSS) Database Research Group. Site of infection impacts presence and severity of septic AKI. American Society for Nephrology 2012 136) Rimmer E, Kumar A, Houston D, Doucette S, Zarychanski R. Activated protein C and septic shock: A propensity-matched cohort study. Crit Care Med 2011;39 (suppl): #39

57

137) Rimmer E, Kumar A, Turgeon A, Makar B, Houston D, Zarychanski R. Clinical use of activated protein C inn septic shock: Results from a multinational cohort. Crit Care Med 2011;39 (suppl): #392 138) Makar B, Weldon E, Webb A, Peters H, Turgeon A, Houston D, Rimmer E, Kumar A, Zarychanski R. Frozen plasma to red blood cell ratio and mortality in patients requiring massive transfusion. Crit Care Med 2011;39 (suppl): #282 139) Kethireddy S, Funk D, Kumar A. Septic shock from Mycobacterium tuberculosis. Crit Care Med 2011;39 (suppl): #532 140) Funk D, Kethireddy S, Doucette S, Kumar A. Use of low dose (stress) corticosteroids in patients with septic shock. Crit Care Med 2011;39 (suppl): #289. 141) Dara SI, Arabi YM, Tamim HM, Rishu AH, Kumar A. Pneumonia as a cause of septic shock is not associated with worse outcomes compared to non-pneumonia causes. ATS 2012 142) Al-Dorzi HM, Tamim H, Bouchama A, Kumar A, Arabi YM. Presentation and outcome of diabetic patients admitted with septic shock. ATS 2012 143) Dara SI, Arabi YM, Tamim HM, Rishu AH, Kumar A. Female Gender and Outcomes Among Patients Admitted With Septic Shock. ATS 2012 144) Kumar A and the ROSII Investigators. Viral Clearance with Standard or Triple Dose Oseltamivir Therapy in Critically Ill Patients with Pandemic (H1N1) 2009 Influenza. ICAAC 2013 145) Kethireddy S, Light RB, Mirzanejad Y, Maki D, Simon D, Kumar A, Parrillo JE, Kumar A and the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Group. Characteristics And Outcomes Of Patients With Culture Negative Septic Shock Compared To Patients With Culture Positive Septic Shock: A Retrospective Cohort Study. International Sepsis Forum 2013 146) Bednarczyk J, Kethireddy S, White CW, Freed DH, Bell D, Kumar A, Light B. Extracorporeal Membrane Oxygenation facilitates Survival in Blastomycosis related Acute Respiratory Distress Syndrome. Canadian Critical Care Forum 2013. 147) Rimmer E, Houston B, Kumar A, Abou-Setta AM, Friesen C

3, Turgeon AF, Cook

DJ, Houston DS, Zarychanski R. The Efficacy and Safety of Therapeutic Apheresis in Patients with Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. Canadian Critical Care Forum 2013

58

148) Mooney O, Bell D, Turgeon A, Kumar A, Houston D, Rimmer E, Zarychanski R. Nucleated Red Blood Cells as an Independent Predictor of ICU Mortality and Recidivism. Canadian Critical Care Forum 2013. 149) Craig J, Daneman N, Rishu A, Xiong

W, Bagshaw SM, Dodek PE, Hall

R, Kumar

A, Lamontagne F, Lauzier

F, Marshall J, Martin C, McIntyre

L, Muscedere J, Reynolds

S,

Stelfox HT, Fowler

R for the BALANCE Study Group. Adjudication of Duration Of

Adequate Antimicrobial Treatment In Critical Care. Canadian Critical Care Forum 2013 150) Rishu

A, Daneman N, Xiong


R, Kumar

A,

Lamontagne F, Lauzier



S,

Stelfox HT, Fowler

R for the BALANCE Study Group. Description Of Duration Of

Treatment For Bloodstream Infection In Critically Ill Patients: A Multi-Centre Observational Study. Canadian Critical Care Forum 2013 151) Daneman N , Rishu

A, Xiong


R, Kumar

A,

Lamontagne F, Lauzier



S,

Stelfox HT, Fowler

R for the BALANCE Study Group. Patient And Pathogen Predictors

Of Antibiotic Treatment Duration For Bloodstream Infection In Critically Ill Patients. Canadian Critical Care Forum 2013 152) Rimmer E, Houston B, Kumar A, Abou-Setta AM, Friesen C

3, Turgeon AF, Cook

DJ, Houston DS, Zarychanski R. The Efficacy and Safety of Therapeutic Apheresis in Patients with Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. American Society of Hematology 2013. 153) Daneman N, Rishu A, Xiong W, Bagshaw SM, Dodek PM, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall JC, McIntyre LA, Martin C, Muscedere J, Reynolds S, Stelfox HT, Fowler R: Patient And Pathogen Predictors Of Antibiotic Treatment Duration For Bloodstream Infection In Critically Ill Patients. B48-Sepsis and Pneumonia: Treatment And Outcomes, American Thoracic Society Annual Symposium, May 19, 2014, San Diego, USA. 154) Craig J, Daneman N, Rishu A, Xiong W, Bagshaw SM, Dodek PM, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall JC, McIntyre LA, Martin C, Muscedere J, Reynolds S, Stelfox HT, Fowler R: Measuring The Duration Of Adequate Antimicrobial Treatment For Blood Stream Infections In Critically Ill Patients. B48-Sepsis and Pneumonia: Treatment And Outcomes, American Thoracic Society Annual Symposium, May 19, 2014, San Diego, USA. 155) Rishu A, Daneman N, Xiong W, Bagshaw SM, Dodek PM, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall JC, McIntyre LA, Martin C, Muscedere J, Reynolds S, Stelfox HT, Fowler R: Description Of Duration Of Treatment For Bloodstream Infection In Critically Ill Patients: A Multi-Centre Observational Study. B48-Sepsis and

59

Pneumonia: Treatment And Outcomes, American Thoracic Society Annual Symposium, May 19, 2014, San Diego, USA. 156) Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A. Houston DS ; Rimmer E, Houston BL, McIntyre L, Fox-Robichaud AE, Hebert PC, Cook DJ, Fergusson DA. The efficacy and safety of heparin in patients with sepsis: a systematic review and meta-analysis Belgium 2015 157) Menard CE, Kumar A, Rimmer E, Houston D, Houston B, Turgeon AF, and Zarychancki R. Thrombocytopenia in Septic Shock. European Society of Intensive Care Medicine 2016 Meeting. Milan, Italy, Oct 3 2016 158) Roberts RJ, Vasquez-Grande G, Esfahani EK, Pisipati A, Kumar A, Devlin JW. Impact of Antibiotic Initiation Sequencing on Outcomes in Patients with Septic Shock. Society of Critical Care Medicine 2017 Scientific Symposium. Honolulu, Hawaii, Jan 2017.

invited lectures (extra-mural) 1) Mechanisms of myocardial cell depression in human septic shock. Award Lecture. Society for Critical Care Medicine Annual Scientific Session (New York, NY) April 1993 2) SIRS (systemic inflammatory response syndrome), sepsis and septic shock. American Academy of Neurology Annual Scientific Symposium (Washington, DC) May 1994 3) Sepsis and septic shock. University of Wisconsin 13th Annual Critical Care Symposium (Madison, WI) September 1995 4) The nature of myocardial dysfunction in human septic shock. Merck J. Wayne Ebrite Infectious Diseases Research Conference. (West Point, PA) November 1995 5) Pharmacology of vasoactive drugs. Society of Critical Care Medicine Board Review Course (Chicago, IL) August 1997 6) Central nervous system infections. Society of Critical Care Medicine Board Review Course (Chicago, IL) August 1997 7) Pathogenesis and therapy of sepsis and septic shock. University of Wisconsin 14

th

Annual Critical Care Symposium (Madison, WI) October 1997 8) Infections in the immunosuppressed. Society of Critical Care Medicine Review Course (San Antonio, TX) February 1998

60

9) Poster Moderator: Sepsis. Society of Critical Care Medicine Annual Scientific Symposium (San Antonio, TX) February 1998 10) Ethics and the Law: Withdrawal of Life Support in Non-Brain Dead Critically Ill Patients. Holy Cross Hospital Ethics Symposium, (Chicago, IL) April 1998 11) Pharmacology of vasoactive drugs. Society of Critical Care Medicine Board Review Course (Chicago, IL) August 1998 12) Central nervous system infections. Society of Critical Care Medicine Board Review Course (Chicago, IL) August 1998 13) Life-threatening infections in the immunosuppressed. Critical Care Medicine Grand Rounds. Los Angeles County Hospital (Los Angeles, CA) July 1998 14) Role of cytokines and nitric oxide in septic myocardial dysfunction. Critical Care Medicine Grand Rounds. University of Wisconsin at Madison (Madison, WI) September 1998 15) Antimicrobials in the ICU: Beyond Bugs and Drugs. Society of Critical Care Medicine Refresher Course (San Francisco, CA) February 1999 16) Nosocomial and ventilator-associated pneumonia. Society of Critical Care Medicine Refresher Course (San Francisco, CA) February 1999 17) Poster Moderator: Cardiovascular Physiology. Society of Critical Care Medicine Annual Scientific Symposium (San Francisco, CA) February 1999 18) On the rational use of antibiotics in the ICU. University of Wisconsin 16

th Annual

Critical Care Symposium (Madison, WI) October 1999 19) Nosocomial and ventilator-associated pneumonia. University of Wisconsin 16

th

Annual Critical Care Symposium (Madison, WI) October 1999 20) Septic Myocardial Depression: From bedside to bench and back. NIH Institute on Aging, Cardiovascular Research Labs. Invited Lecture (Baltimore, MD) November 1999 21) Poster Moderator: Cytokines and Sepsis. Society of Critical Care Medicine Annual Scientific Symposium (Orlando, FL) February 2000 22) Septic Shock: Old Precepts, New Concepts. Lutheran General Hospital, Grand Rounds (Chicago, IL) September 2000 23) Fungal Infections and Resistance. Society of Critical Care Medicine Refresher Course (San Francisco, CA) February 2001

61

24) Poster Moderator: Sepsis Models. Society of Critical Care Medicine Annual Scientific Symposium (San Francisco, CA) February 2001 25) Septic Myocardial Depression. From Bench to Bedside. University of Wisconsin, Critical Care Grand Grounds (Madison, WI) March 2001 26) Septic Myocardial Depression. From Bench to Bedside. University of Calgary, Critical Care Research Rounds (Calgary, Alberta) April 2001 27) Optimization of Antibiotic Use in the ICU. University of Calgary, Critical Care Grand Rounds (Calgary, Alberta) April 2001 28) National Initiative on Sepsis Lectures: Antibiotic Issues, Supportive Care and the Team Approach (Boston, MA) April 28, 2001 29) National Initiative on Sepsis Lectures: Definitions, Epidemiology, Antibiotic Issues and Case Studies (Los Angeles, CA) May 19, 2001 30) National Initiative on Sepsis Lectures: Antibiotic Issues, Supportive Care, the Team Approach and Pathways/Guidelines (Chicago, IL) June 19, 2001 31) Septic Shock: Old Precepts, New Concepts. University of Illinois. Continuing Medical Education Lecture (Chicago, IL) July 10, 2001 32) Septic Shock: Old Precepts, New Concepts. St. Mary’s Hospital. Grand Rounds (Hobart, IN) August 8, 2001 33) Septic Shock: Old Precepts, New Concepts. University of Manitoba. Continuing Medical Education Lecture (Winnipeg, Manitoba) August 18, 2001 34) National Initiative on Sepsis Lectures: Antibiotic Issues, Supportive Care and the Team Approach (Laguana Nigel, CA) August 18, 2001 35) Septic Shock: Old Precepts, New Concepts. St. Joseph’s Hospital. Grand Rounds (Chicago, IL) August 29, 2001 36) Septic Shock: Old Precepts, New Concepts. St. Joseph Exempla Hospital. Grand Rounds (Denver, CO) September 7, 2001 37) Septic Shock: Old Precepts, New Concepts. Holy Cross Hospital. Grand Rounds (Chicago, IL) Oct 3, 2001 38) Septic Shock: Old Precepts, New Concepts. St. James Hospital. Grand Rounds (Chicago, IL) Oct 11, 2001

62

39) Septic Shock: Old Precepts, New Concepts. University of Wisconsin, Milwaukee. Continuing Medical Education Lecture (Milwaukee, WI) Oct 11, 2001 40) National Initiative on Sepsis Regional Lecture: Sepsis and Septic Shock (Chicago, IL) November 1, 2001 41) National Initiative on Sepsis Lectures: Antibiotic Issues, Supportive Care, the Team Approach and Case Studies (Philadelphia, PA) November 3, 2001 42) National Initiative on Sepsis Regional Lecture: Sepsis and Septic Shock (Columbus, OH) November 13, 2001 43) On the Optimal Use of Antimicrobials in the ICU: Beyond Bugs and Drugs. Critical Care Regional Conference (Pittsburgh, PA) November 17, 2001 44) On the Optimal Use of Antimicrobials in the ICU: Beyond Bugs and Drugs. Concordia Hospital Grand Rounds (Winnipeg, Manitoba) November 20, 2001 45) Septic Shock: New Concepts in Pathophysiology. University of Wisconsin 17

th

Annual Critical Care Symposium (Madison, WI) November 29, 2001 46) Sepsis and Septic Shock: Cases Studies. University of Wisconsin 17

th Annual

Critical Care Symposium (Madison, WI) November 30, 2001 47) National Initiative on Sepsis Lectures: Antibiotic Issues, Supportive Care, Pathways/Guidelines and Case Studies (San Diego, CA) December 8, 2001 48) National Initiative on Sepsis Lectures: Antibiotic Issues, Supportive Care, the Team Approach and Pathways/Guidelines (St. Louis, MO) December 15, 2001 49) Septic Shock: Old Precepts, New Concepts. City-wide Critical Care Lecture (Winnipeg, Manitoba) January 16, 2001 50) Poster Moderator: Cardiovascular Physiology. Society of Critical Care Medicine Annual Scientific Symposium (San Diego, CA) January 2002 51) Septic Shock: Old Precepts, New Concepts. St. Catherine’s Hospital. Grand Rounds (East Chicago, IL) February 7, 2002 52) The Spectrum of Sepsis: Case Studies. St. Francis Medical Center. Continuing Medical Education Lecture. (Pittsburgh, PA) February 12, 2002 53) Septic Shock: Old Precepts, New Concepts. St. Francis Medical Center, Grand Rounds (Pittsburgh, PA) February 13, 2002

63

54) Septic Myocardial Depression: From Bedside to Bench and Back. National Research Council, Institute for Biodiagnostics. Invited Research Lecture (Winnipeg, MB) February 15, 2002 55) The Spectrum of Sepsis: Case Studies. Grace General Hospital. Emergency Department Grand Rounds. (Winnipeg, MB) March 12, 2002 56) Septic Shock: Current Management Strategies. St. Luke’s Medical Center. Continuing Medical Education (Duluth, MN) April 9, 2002 57) Septic Shock: Old Precepts, New Concepts. Cambridge Hospital, Grand Rounds (Cambridge, MN) April 10, 2002 58) Antibiotics in Sepsis and Septic Shock. University of North Dakota Medical Center, Grand Rounds (Grand Forks, ND) April 11, 2002 59) On the Optimal Use of Antimicrobials in the ICU: Beyond Bugs and Drugs. Critical Care Regional Conference (New York, NY) April 27, 2002 60) Septic Shock: Old Precepts, New Concepts. Hospital HIMA, Grand Rounds (Caguas, Puerto Rico) May 21, 2002 61) Antibiotics in Sepsis and Septic Shock. Hospital La Concepcion, Grand Rounds (San German, Puerto Rico) May 22, 2002 62) Septic Shock: Old Precepts, New Concepts. Hospital San Cristobal Grand Rounds (Coto Laurel, Puerto Rico) May 23, 2002 63) National Initiative on Sepsis Lectures: Infectious Diseases Issues, Hemodynamic Support, Bioterrorism and Ethical Considerations (Miami, FL) June 8, 2002 64) National Initiative on Sepsis Lectures: Infectious Diseases Issues, Hemodynamic Support, Bioterrorism and Ethical Considerations (San Antonio, TX) June 22, 2002 65) National Initiative on Sepsis Lectures: Infectious Diseases Issues, Hemodynamic Support, Bioterrorism and Ethical Considerations (Gainesville, FL) June 29, 2002 66) Coagulation Abnormalities in Sepsis and Septic Shock. Biannual Conference on Hemostasis and Coagulation. (Madison, WI) November 11-12, 2002. 67) Convener, Sepsis Forum. Rocky Mountain Critical Care Conference. (Silver Star Mountain Resort, BC) February 20-22, 2003 68) Management of Life-Threatening Fungal Infections in the ICU. City Wide Critical

64

Care Rounds. University of Manitoba (Winnipeg, MB) May 29, 2003 69) Immediate Management Issues in Sepsis and Septic Shock. Canadian Association of Emergency Physicians Annual Meeting, (Winnipeg, MB) June 7, 2003 70) Septic Shock: Old Precepts, New Concepts. Critical Care Grand Rounds. Brandon General Hospital (Brandon, MB) June 17, 2003 71) Shock: A Graphical Analysis based on Venous Return. Critical Care Rounds. Health Sciences Centre (Winnipeg, MB) November 14, 2004 72) Septic Shock: The Sepsis Sixpack, An Overview of Therapy of Sepsis and Septic Shock. Critical Care Rounds. (Winnipeg, Manitoba) January 12, 2004 73) Septic Shock: Emerging Considerations in Early Management. Medical Grand Rounds. Health Sciences Centre and St. Boniface Hospital, University of Manitoba. (Winnipeg, MB). January 28, 2004 74) Lack of Utility of PAC-Derived PWP and CVP to Predict Ventricular Volumes and Stroke Volume Response in Normal Humans. Society of Critical Care Medicine Annual Scientific Symposium (Orlando, FL) February 20, 2004

75) Poster Moderator: Clinical Science: Sepsis/Infection. Society of Critical Care Medicine Annual Scientific Symposium (Orlando, FL) February 2004 76) Poster Moderator: Cardiovascular Disease. Society of Critical Care Medicine Annual Scientific Symposium (Orlando, FL) February 2004 77) An Update on Sepsis and Septic Shock. Anesthesia Grand Rounds. University Hospital, University of Cincinnati (Cincinnati, OH) June 25, 2004. 78) Sepsis and Septic Shock: Old Precepts, New Concepts. SCCM Multidisciplinary Review Course (Chicago, IL) August 2004 79) Life Threatening Pneumonia. SCCM Multidisciplinary Review Course (Chicago, IL) August 2004 80) Optimization of Antimicrobial Therapy (Tutorial Review). SCCM Multidisciplinary Review Course (Chicago, IL) August 2004 81) Sepsis and Septic Shock: An update. Harper Hospital/Wayne State University Critical Care Grand Rounds (Detroit, MI) November 2, 2004 82) On the Optimal Use of Antimicrobials in the ICU: Beyond Bugs and Drugs. City-wide Critical Care Rounds (Regina, SK) November 30, 2004

65

83) Sepsis and Septic Shock: Old Precepts, New Concepts. City-wide Critical Care Conference (Saskatoon, SK) December 1, 2004 84) Sepsis and Septic Shock: Diagnosis and Management. E-test Application Laboratory, AbBiodisk Inc. MIC and PK/PD for Critical Care: Challenges and Solutions. (Stockholm Sweden) November 2, 2004 85) Optimal Use of Antimicrobial Agents in the ICU. Beyond Bugs and Drugs. E-test Application Laboratory, AbBiodisk Inc. MIC and PK/PD for Critical Care: Challenges and Solutions. (Stockholm, Sweden) November 2, 2004 86) Poster Moderator: Cardiovascular Physiology. Society of Critical Care Medicine Annual Scientific Symposium (Phoenix, AZ) January 2005 87) Cardiovascular Dysfunction in Sepsis and Septic Shock: From Bench to Bedside and Back. 1

st International Critical Care Medicine Symposium. March 6-10, 2004,

National Guard Health Affairs, Riyadh, Saudi Arabia. 88) Central Nervous System Infections. 1

st International Critical Care Medicine

Symposium. March 6-10, 2004, National Guard Health Affairs, Riyadh, Saudi Arabia. 89) Optimization of Antibiotics in the Critically Ill. Beyond bugs and drugs. 1

st

International Critical Care Medicine Symposium. March 6-10, 2004, National Guard Health Affairs, Riyadh, Saudi Arabia. 90) Fungal Infections in the ICU: Focus on Candida. (Winnipeg, MB) March 15, 2005. 91) Septic Myocardial Depression: From Bench to Bedside and Back. City-Wide Pulmonary Research Conference (Winnipeg, MB), May 4, 2005 92) Septic Myocardial Depression: From Bench to Bedside and Back. Department of Pharmacology Research Conference, University of Manitoba (Winnipeg, MB), May 6, 2005. 93) Optimization of Antimicrobial Therapy in Life-Threatening Infection in the ER. City-wide Emergency Medicine Conference (Winnipeg, MB) May 11, 2005. 94) Life threatening fungal infections in the ICU: Focus on Candida. Merck Canada Annual Sales Meeting, Four Seasons Hotel (Toronto, ON) June 23, 2005 95) Life threatening fungal infections in the ICU: Focus on Candida. Grand Rounds, St. Joseph’s Hospital (Toronto, ON) June 28, 2005 96) Life threatening fungal infections in the ICU: Focus on Candida. Grand Rounds, Lakeridge Community Hospital (Oshawa, ON) June 29, 2005

66

97) Life threatening fungal infections in the ICU: Focus on Candida. Critical Care Medicine Grand Rounds, Toronto General Hospital (Toronto, ON) June 29, 2005 98) Life threatening fungal infections in the ICU: Focus on Candida. Infectious Diseases Grand Rounds, Toronto General Hospital (Toronto, ON) June 29, 2005 99) Life Threatening Pneumonia. SCCM Multidisciplinary Review Course (Chicago, IL) August 2005 100) Optimization of Antimicrobial Therapy (Tutorial Review). SCCM Multidisciplinary Review Course (Chicago, IL) August 2005 101) Septic Shock: Lessons from the Co-operative Antimicrobial Therapy of Sepsis Database: The Good, Bad and the Ugly. University of Manitoba Department of Medicine Grand Rounds, Health Sciences Centre (Winnipeg, Manitoba), September 27, 2005 102) Molecular biology of septic shock. Critical Care Fellows Lecture. Health Sciences Centre (Winnipeg, MB) September 28, 2005 103) Septic Shock: Lessons from the Co-operative Antimicrobial Therapy of Septic Shock Database: The Good, Bad and the Ugly. Grand Rounds, St. Boniface General Hospital (Winnipeg Manitoba), October 20, 2005 104) Septic Shock: Lessons from the Co-operative Antimicrobial Therapy of Sepsis Database: The Good, Bad and the Ugly. Bristol Myers Squibb Advisory Meeting (Toronto, Ontario), October 25, 2005 105) Septic Shock: Lessons from the Co-operative Antimicrobial Therapy of Septic Shock Database: The Good, Bad and the Ugly. Infectious Diseases/Medical Microbiology Fellows Lecture, University of Manitoba, Health Sciences Centre (Winnipeg Manitoba), November 23, 2005 106) Septic Shock: Lessons from the Co-operative Antimicrobial Therapy of Septic Shock Database: An ER Perspective. City-wide ER Grand Rounds. St. Boniface Research Centre (Winnipeg, MB) January 26, 2006 107) Epidemiology of Septic Shock in Manitoba and Canada: Lessons from the Co-operative Antimicrobial Therapy of Septic Shock Database. University of Manitoba, Department of Community Heath Sciences (Winnipeg, MB) February 17, 2006 108) Septic Shock: Lessons from the Co-operative Antimicrobial Therapy of Septic Shock Database: The Good, Bad and the Ugly. Canadian Critical Care Conference (Whistler BC) Feb 23, 2006

67

109) Septic Shock: The importance of timing considerations in antimicrobial therapy. Lilly Critical Care Global Medical Conference (in conjunction with the 26

th International

Symposium on Intensive Care and Emergency Medicine)(Brussels Belgium) March 20, 2006. 110) CSI: Winnipeg. Current investigations in sepsis and septic shock. Annual Critical Eye Nursing Conference, University of Manitoba (Winnipeg, Manitoba) April 10, 2006 111) Pathophysiology and Management of Septic Shock: A Renal Perspective. Canadian Society of Nephrology Annual Meeting 2006 (Quebec City, QC) May 26, 2006 112) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Wyeth Advisory Board Meeting (Toronto, ON) October 15, 2006 113) Septic Shock: Optimizing outcome by optimizing antimicrobial therapy. University of California, Bakersfield Grand Rounds, Kern Medical Centre (Bakersfield, CA). October 19, 2006 114) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Toronto Critical Care Medicine Symposium (Toronto, ON) October 27, 2006 115) Antimicrobial therapy of sepsis and septic shock. International Nosocomial Infection Symposium (Winnipeg, MB) Nov 30, 2006. 116) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. St. Agnes Hospital Critical Care Grand Rounds (Baltimore, Maryland) December 13, 2006 117) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Cooper University Hospital Critical Care Grand Rounds (Camden, NJ) December 14, 2006 118) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Association of Medical Microbiology and Infectious Diseases Canada and Canadian Association for Clinical Microbiology and Infectious Diseases Annual Conference (Halifax, NS) March 15, 2007 119) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Grand Rounds, Queen Elizabeth Medical Center, Dalhousie Medical School (Halifax, NX) March 16, 2007

68

120) Antimicrobial and supportive therapy of sepsis and septic shock. Winnipeg Regional Health Authority ER Triage Nurse Educational Meetings (Winnipeg, MB) April 4, 2007. 121) Antimicrobial and supportive therapy of sepsis and septic shock. Winnipeg Regional Health Authority ER Triage Nurse Educational Meetings (Winnipeg, MB) April 5, 2007. 122) Antimicrobial and supportive therapy of sepsis and septic shock. Winnipeg Regional Health Authority ER Triage Nurse Educational Meetings (Winnipeg, MB) April 11, 2007. 123) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Infectious Diseases Grand Rounds, Victoria Hospital, University of London, Faculty of Medicine (London, ON) April 25, 2007 124) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. University Health Network CME Rounds, University of Toronto (Toronto, ON) April 25, 2007 125) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Medical/Surgical Grand Rounds, Grand River/Kitchener-Waterloo Hospital (London, ON) April 26, 2007 126) Septic Shock: Optimizing Outcomes. Critical Care Medicine City-wide Grand Rounds, Victoria Hospital, University of London, Faculty of Medicine (London, ON) April 27, 2007 127) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Medical/Surgical Grand Rounds, Nanaimo Regional General Hospital (Nanaimo, BC) May 1, 2007 128) Septic Shock: Optimizing Outcomes. Royal Jubilee/Victoria General Hospitals Combined CME Rounds, University of Victoria, Faculty of Medicine (Victoria, BC) May 1, 2007 129) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Royal Columbian Hospital CME Lecture (New Westminster, BC) May 2, 2007 130) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Respiratory/Critical Care Medicine Rounds, Surrey Memorial Hospital (Surrey, BC) May 3, 2007 131) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of

69

Septic Shock (CATSS) Database. Vancouver General Hospital/St. Paul’s Hospital CME Lecture (Vancouver, BC) May 3, 2007 132) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Regina Regional Health Authority CME lecture (Regina, SK) June 4, 2007 133) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Medicine Rounds, University Hospital (Edmonton, AB) June 5, 2007 134) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Medicine Rounds, Foothills Hospital, University of Calgary (Calgary, AB) June 6, 2007 135) Sepsis and Septic Shock. Optimizing Outcomes. Grand Rounds, Southlake Hospital (Newmarket, ON) June 25, 2007 136) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Grand Rounds, Humber River Regional Hospital (Weston, ON) June 25, 2007 137) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Medicine Rounds, Hamilton General Hospital, McMaster University (Hamilton, ON) June 25, 2007 138) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Infectious Diseases Rounds, Sunnybrook Hospital, University of Toronto (Toronto, ON) June 26, 2007 139) Sepsis and Septic Shock. Optimizing Outcomes. Tri-hospital Critical Care CME lecture, Sunnybrook, North York General, Scarborough General Hospitals (Toronto, ON) June 26, 2007 140) Sepsis and Septic Shock. Optimizing Outcomes. Critical Care Medicine Rounds, Windsor Regional Hospital and Hotel Dieu Grace Hospital (Windsor, ON) June 27, 2007 141) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Grand Rounds. University of Wisconsin Hospital and Clinics (Madison, WI) Sept 11, 2007. 142) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Symposium Lecture. Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL) Sept 17, 2007

70

143) Diagnosis and Management of Septic Shock. Critical Care Grand Rounds, Rush University and Medical Center (Chicago, IL) Sept 18, 2007 144) Management of Septic Shock. ICU Grand Rounds. St. Joseph’s Hospital and the Sudbury Regional Health Authority (Sudbury, ON) Sept 24, 2007 145) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Sudbury Regional Health Authority CME lecture (Sudbury ON) Sept 24, 2007 146) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. City-wide Pharmacy Grand Rounds, Princess Margaret Hospital (Toronto, ON) Sept 25, 2007 147) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. City-wide Critical Care Rounds. St. Michael’s Hospital (Toronto, ON) Sept 25, 2007 148) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Surgery Grand Rounds. McMaster University Medical Center (Hamilton, ON) Sept 26, 2007 149) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. ER Grand Rounds. St. Joseph’s Hospital (Hamilton, ON) Sept 26, 2007 150) Management of Septic Shock. St. Catherines Regional Health Authority ER Grand Rounds (St. Catherines, ON) Sept 26, 2007 151) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Surgery Grand Rounds. Grand River Hospital (Kitchener, ON) Sept 27, 2007 152) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Rounds. Victoria Hospital, London Health Sciences Centre. (London, ON) Sept 27, 2007 153) Management of Septic Shock. Pharmacy/ID Conjoint Rounds. London Health Sciences Centre (London, ON) Sept 27, 2007. 154) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Rounds. St. Paul’s Hospital (Vancouver, BC) Oct 11, 2007

71

155) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. IDology Club. Ottawa General and Ottawa Civic Hospitals. (Ottawa, ON) Oct 15, 2007 156) Optimization of Antimicrobial Therapy in Septic Shock: Speed is Life. Critical Care Rounds. Pharmacy Grand Rounds. (Ottawa, ON) Oct 16, 2007 157) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. 16

th Critical Care Medicine Conference,

University of Wisconsin (Madison, WI) Oct 23, 2007 158) Cardiovascular Dysfunction in Septic Shock: From Bench to Bedside and Back. Canadian Critical Care Forum (Toronto, ON) Oct 30, 2007 159) Managing Infections in the Immuno-suppressed Patient. Canadian Critical Care Forum (Toronto, ON) Oct 30, 2007 160) Managing Fungal Sepsis and Septic Shock. Canadian Critical Care Forum (Toronto, ON) Nov 1, 2007 161) Optimizing Antimicrobial Management of Septic Shock: Speed is Life. Canadian Critical Care Forum (Toronto, ON) Nov 1, 2007 162) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. ICU and ID/Micro Interhospital Rounds. Pierre Boucher Hospital (Monteregie, QC) Nov 14, 2007. 163) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. McGill University Interdepartmental Rounds, Jewish General Hospital (Montreal, QC) Nov 14, 2007 164) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Montreal General Hospital CME Lecture (Montreal, QC) Nov 14, 2007 165) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. CHUM ICU/ID/Microbiology Interhospital Video-Conference, Notre Dame Hospital (Montreal, QC) Nov 15, 2007 166) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Medical Grand Rounds, Maisonneuve-Rosemont Hospital (Montreal, QC) Nov 15, 2007 167) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Quebec City Inter-hospital CME Lecture (Quebec

72

City, QC) Nov 15, 2007. 168) Optimzing Outcomes in Septic Shock: Speed is Life. University of Massachusetts Medical Center Medical Grand Rounds (Boston, MA) Nov 29, 2007. 169) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Apollo Hospital CME Lecture (New Delhi, Uttar Pradesh, India) Dec 5, 2007. 170) Principles of Treating Infectious Diseases in Critical Care. Multiprofessional Board Review Course (Course Director, Anand Kumar), Asia Pacific Conference on Critical Care (New Delhi, Uttar Pradesh, India) Dec 6, 2007 171) Life-threatening Infections in the Immunosuppressed. Multiprofessional Board Review Course (Course Director, Anand Kumar), Asia Pacific Conference on Critical Care (New Delhi, Uttar Pradesh, India) Dec 6, 2007 172) Shock and Basic Hemodynamic Monitoring. Multiprofessional Board Review Course (Course Director, Anand Kumar), Asia Pacific Conference on Critical Care (New Delhi, Uttar Pradesh, India) Dec 6, 2007 173) Optimizing Antimicrobial Management of Sepsis and Septic Shock. Asia Pacific Conference on Critical Care (New Delhi, Uttar Pradesh, India) Dec 8, 2007 174) Management of Fungal Sepsis and Septic Shock: Emerging Concepts in Diagnosis and Management. Asia Pacific Conference on Critical Care (New Delhi, Uttar Pradesh, India) Dec 8, 2007 175) Utility of PA Catheters and CVP in Critically Ill. Asia Pacific Conference on Critical Care (New Delhi, Uttar Pradesh, India) Dec 9, 2007 176) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Max Super-Specialty Hospital Grand Rounds (New Delhi, Uttar Pradesh, India) Dec 5, 2007. 177) Optimizing Outcome in Septic Shock. Multispecialty Grand Rounds. Altru Medical Center, University of North Dakota (Grand Forks, ND) Jan 16, 2008 178) Antimicrobial Use in the ICU. Medical Microbiology Rounds, University of Manitoba (Winnipeg, MB) Jan 21, 2008 179) Antimicrobial Use in Septic Shock. Medical Microbiology Rounds, University of Manitoba (Winnipeg, MB) Jan 28, 2008 180) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of

73

Septic Shock (CATSS) Database. Interdisciplinary ICU/Microbiology/ID Rounds, Royal Glamorgan Hospital (Cardiff, Wales, Great Britain) Feb 25, 2008 181) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Interdisciplinary ICU/Microbiology/ID Rounds, Southampton University Hospital (Southampton, England) Feb 26, 2008 182) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. The London Intensive Care Group City-Wide Rounds, St. Thomas Hospital (London, England) Feb 26, 2008 183) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. ICU/Microbiology/ID Rounds, Birmingham Heartlands Hospital (Birmingham, England) Feb 27, 2008 184) Optimizing Antimicrobial Management of Sepsis and Septic Shock. City-wide ITS/ICU Conference, Birmingham Heartland Hospital (Birmingham, England) Feb 27, 2008 185) Interactive Pneumonia Case History: Focus on Pathogen and Antibiotic Treatment. 1

st Intensivists Forum, Hilton Vienna Hotel (Vienna, Austria) Feb 28,

2008 186) Saving Lives with Early Antimicrobial Intervention: Speed is Life. 1

st

Intensivists Forum, Hilton Vienna Hotel (Vienna, Austria) Feb 29, 2008 187) Optimizing Outcome in Septic Shock: Lessons from the CATSS database, Speed is Life: Part 1. 3º Simpósio de Infecção e Sépsis 2008, Sheraton Hotel (Porto, Portugal) April 3, 2008 188) Optimizing Outcome in Septic Shock: Lessons from the CATSS database, Speed is Life: Part 2. 3º Simpósio de Infecção e Sépsis 2008, Sheraton Hotel (Porto, Portugal) April 3, 2008 189) Optimizing Outcome in Septic Shock: Lessons from the CATSS database, Speed is Life: Part 1. Medical Grand Rounds, Toronto East General Hospital (Toronto, ON) April 16, 2008 190) Optimizing Outcome in Septic Shock: Lessons from the CATSS database, Speed is Life: Part 1. Grand Rounds, William Osler Medical Center (Toronto, ON) April 16, 2008 191) Optimizing Outcome in Septic Shock: Lessons from the CATSS database, Speed is Life: Part 1. Critical Care Rounds, Southlake Hospital (Richmond, ON) April 16, 2008

74

192) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Rounds, Queens University Hospital (Kingston, ON) April 17, 2008 193) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Rounds, Gold Coast Hospital (Brisbane, Australia) April 28, 2008 194) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Rounds, Royal Brisbane and Women’s Hospital (Brisbane, Australia) April 28, 2008 195) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Combined Critical Care and Infectious Diseases Rounds, Royal Melbourne Hospital (Melbourne, Australia) April 29, 2008 196) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Infectious Diseases Rounds, Monash Medical Centre (Melbourne, Australia) April 29, 2008 197) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Rounds, Peter MacCallum Cancer Institute (Melbourne, Australia) April 30, 2008 198) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Combined Critical Care and Infectious Diseases Rounds, Royal Adelaide Hospital (Adelaide, Australia) April 30, 2008 199) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Combined Critical Care and Infectious Diseases Rounds, Royal North Shore Hospital (Sydney, Australia) April 30, 2008 200) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Combined Critical Care and Infectious Diseases Rounds, Westmead Hospital (Sydney, Australia) April 30, 2008 201) A Novel Paradigm of the Pathogenesis of Septic Shock: Predictions and Implications for Management. Special Consulting Lecture. Astra-Zeneca Corporate and Research Center (Wilmington, DE) May 14, 2008 202) Optimizing Outcomes in Fungal Sepsis and Septic Shock. Centre hospitalier de l’Université de Montréal (CHUM) ICU Critical Care Conference (Montreal, QC) June 5, 2008

75

203) Optimizing Outcomes in Fungal Sepsis and Septic Shock. Medical-Surgical Grand Rounds, Hospital Maissoneuve-Rosemont (Montreal, QC) June 5, 2008 204) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Continuing Education Conference (Montreal, QC) June 5, 2008 205) ICU Management of Gram Positive Septicemia . 4th International Symposium on Resistant Gram-Positive Infections. State University of New York (Buffalo, NY) July 10, 2008 206) Infections in AIDS, Transplant Patients and Other Immunocompromised Hosts. Society of Critical Care Medicine Multiprofessional Critical Care Review Course. (Chicago, IL) August 7, 2008 207) Multi-resistant Infections. Society of Critical Care Medicine Multiprofessional Critical Care Review Course. (Chicago, IL) August 7, 2008 208) Speed is Life: Comparison of Antimicrobial and Non-antimicrobial Therapies Impact on Outcome of Septic Shock. Combined Medical Grand Rounds. St. Luke’s Hospital, University of Wisconsin Milwaukee. (Milwaukee, WI) September 4, 2008 209) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Surgical Grand Rounds, Vancouver General Hospital (Vancouver, BC) September 17, 2008 209) Speed is Life: Comparison of Antimicrobial and Non-antimicrobial Therapies Impact on Outcome of Septic Shock. Medical Grand Rounds, St. Paul’s Hospital (Vancouver, BC) September 17, 2008 210) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. City Wide ID Continuing Education Lecture (Vancouver, BC) September 17, 2008 211) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Speed is Life. 6

th International Conference on Intensive Care (Quito, Ecuador) Sept 25, 2008

212) Myocardial Depression in Sepsis and Septic Shock. 6

th International

Conference on Intensive Care (Quito, Ecuador) Sept 25, 2008 213) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Intensifying Therapy. 6

th International Conference on Intensive Care (Quito, Ecuador) Sept 25,

2008 214) Debate: Unilateral With-holding and Withdrawing: Can it ever be done? An

76

intensivist’s perspective. The Grey Matter Symposium in conjunction with Canadian Critical Care Forum Annual Meeting 2008. (Toronto, Canada) Nov 10, 2008 215) Why Delays of Antimicrobials Matter in Septic Shock. Canadian Critical Care Forum Annual Meeting 2008. (Toronto, Canada) Nov 11, 2008 216) Antibiotic Resistance in the ICU: How We Got Here and Where Are We Going? Multispecialty Grand Rounds. Altru Medical Center, University of North Dakota (Grand Forks, ND) Jan 7, 2009 217) Lessons from the Manitoba Septic Shock Database: Local Epidemiologic and Treatment Trends. Medical Grand Rounds. Health Sciences Centre, University of Manitoba (Winnipeg, MB) Jan 27, 2009 218) An Alternate Injury Paradigm for Sepsis and Septic Shock and its Implications for Antimicrobial Therapy. Society of Critical Care Medicine Annual Refresher Course (Nashville, TN) Jan 31, 2009. 219) Monotherapy vs Combination Antimicrobial Therapy of Sepsis and Septic Shock: Combination Therapy Yields Improved Outcome. Society of Critical Care Medicine Annual Scientific Symposium (Nashville, TN) Feb 3, 2009 220) Speed is Life: Optimizing Antimicrobial Management of Septic Shock. Society of Critical Care Medicine Annual Scientific Symposium (Nashville, TN) Feb 4, 2009 221) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Academy of Infection Management Symposium. Metropole Hotel (London, England) March 16, 2009 222) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. University of Wales Hospital (Cardiff, England) March 17, 2009 223) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Southampton Hospital (Southampton, England) March 17, 2009 224) Combination Therapy: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Western General Hospital (Edinburgh, England) March 18, 2009 225) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. University of Manchester University, Wythenshaw Hospital (Manchester, England) March 19, 2009

77

226) Septic Shock: Optimizing Source Control. Surgical Grand Rounds, Health Sciences Centre, University of Manitoba (Winnipeg, MB) April 2, 2008 227) Optimizing Therapy of Life-Threatening Candida Infections. Astellas Advisory Meeting (Montreal, QC) April 17, 2008 228) Getting it Right, Right Now. Optimizing Outcome in Septic Shock. McGill Critical Care Symposium (Montreal, QC) April 24, 2008 229) Preventing ICU Infections. McGill Critical Care Symposium (Montreal, QC) April 24, 2008 230) Septic Shock: Manitoba Epidemiologic and Treatment Trends. Edge of Excellence Conference (Winnipeg, MB) May 11, 2009 231) Optimizing Antimicrobial Therapy in Septic Shock: Code Sepsis: Sepsis syndromes and life-saving therapies. American Society of Microbiology 109

th

General Meeting (Philadelphia, PA) May 20, 2009 232) H1N1 Infection in ICU. Canadian Pandemic Preparedness Meeting: H1N1 Outbreak Research Response (Toronto, ON) July 8, 2009 233) Severe H1N1 In Manitoba ICUs. Canadian Pandemic Preparedness Meeting: H1N1 Outbreak Research Response (Toronto, ON) July 8, 2009 234) Antimicrobial Use in the ICU. Multiprofessional Critical Care Review Course 2009 (San Francisco, CA) July 15, 2009 235) Multi-resistant Infections. Multiprofessional Critical Care Review Course 2009 (San Francisco, CA) July 15, 2009 236) Infections in AIDS, Transplant Patients and other Immunocompromised Hosts. Multiprofessional Critical Care Review Course 2009 (San Francisco, CA) July 16, 2009 237) Lessons from the ICU: The Winnipeg H1N1 Outbreak. Ottawa CME Telecast/Manitoba TeleHealth Service (Winnipeg, MB) July 29, 2009 238) Severe Disease Epidemic Narratives: Description of Clinical Management and Challenges Experienced in Winnipeg ICUs. PHAC Conference: Severe H1N1 Disease: Preventing Cases, Reducing Mortality. (Winnipeg, MB) Sept 2, 2009 239) Adjunctive therapies –what do you have left when oseltamivir fail. PHAC Conference: Severe H1N1 Disease: Preventing Cases, Reducing Mortality. (Winnipeg, MB) Sept 3, 2009

78

240) Severe H1N1 Infection in the ICU. H1N1 Mini-symposium. Weimar Sepsis Update: Sepsis Goes Public. 4

th International Congress on Sepsis and Mult-iorgan

Dysfunction. (Weimar, Germany) Sept 9, 2009 241) Strategies to prevent antibiotic delays. Rationale use of antibiotics in sepsis. Weimar Sepsis Update: Sepsis Goes Public. 4

th International Congress on Sepsis

and Multi-organ Dysfunction. (Weimar, Germany) Sept 10, 2009 242) H1N1: Description of Clinical Management and Challenges Experienced in Winnipeg ICUs. Primera Pandemia de Gripe en UCIs, Sociedad Espanola de Medicina Intensiva, Critica y Unidades Coronarias (Madrid, Spain) Oct 5, 2009 243) Severe H1N1 Infection in Canada. Primera Pandemia de Gripe en UCIs, Sociedad Espanola de Medicina Intensiva, Critica y Unidades Coronarias (Madrid, Spain) Oct 5, 2009

244) Speed is Life: Optimizing Antimicrobial Management of Septic Shock. Critical Care Grand Rounds, Servicio de Medicina Intensiva y Crítica Hospital Universitari de Tarragona Joan XXIII (Tarragona, Spain) October 6, 2009

245) H1N1: Description of Clinical Management and Challenges Experienced in Winnipet ICUs, Servicio de Medicina Intensiva y Crítica Hospital Universitari de Tarragona Joan XXIII (Tarragona, Spain) October 7, 2009 246) ICU Management of Severe H1N1 Infection. WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza (Washington, DC) October 14, 2009 247) Epidemiology of Septic Shock in Canada. Critical Care Canada Forum (Toronto, ON) October 26, 2009 248) Fungal Septic Shock. Critical Care Canada Forum (Toronto, ON) October 26, 2009 249) Diagnosis and Management of Fungal Sepsis. Critical Care Canada Forum (Toronto, ON) October 26, 2009 250) Pathology of Severe H1N1 Infection. Critical Care Canada Forum (Toronto, ON) October 27, 2009 251) Fungal Sepsis and Septic Shock. Critical Care Canada Forum (Toronto, ON) October 27, 2009 252) The Right Antibiotic at the Right Time. Brazilian Congress of Critical Care Medicine (Sao Paulo, Brazil) Nov 11, 2009

79

253) Current Evidence: Monotherapy vs Combination Therapy in Septic Shock. Brazilian Congress of Critical Care Medicine (Sao Paulo, Brazil) Nov 11, 2009 254) Myocardial Dysfunction in Sepsis and Septic Shock: Diagnosis and Treatment. Brazilian Congress of Critical Care Medicine (Sao Paulo, Brazil) Nov 12, 2009 254) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. St. George’s Hospital (South London, England) Dec 14, 2009 254) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. British Intensive Care Society Annual Meeting (London, England) Dec 14, 2009 254) Optimizing Outcomes in Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Sheffield Hallam Teaching Hospital (Sheffield, England) Dec 15, 2009 255) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Aberdeen Royal Infirmary (Aberdeen, Scotland) Dec 16, 2009 256) Optimizing Outcomes in Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. University of Glasgow Medical School (Glasgow, Scotland) Dec 16, 2009 257) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. University College (London) Hospital (London, England) Dec 17, 2009 258) Optimizing Outcomes in Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. King’s College Hospital (London, England) Dec 17, 2009 257) How research is driving clinical outcomes / tales from the front lines of the H1N1 epidemic. Manitoba Health Research Council Presentation. Manitoba Legislature (Winnipeg, MB) Feb 16, 2010 258) Lessons from the frontlines of the H1N1 pandemic. American Thoracic Society State of the Art Review Course. (Miami, FL) Feb 26, 2010 259) My experience with H1N1. 30

th International Symposium on Intensive Care

and Emergency Medicine. (Brussels, Belgium) March 9, 2010

80

260) ECMO in H1N1-associated respiratory failure. 30th International Symposium

on Intensive Care and Emergency Medicine. (Brussels, Belgium) March 10, 2010 261) Antimicrobials in septic shock. 30

th International Symposium on Intensive Care

and Emergency Medicine. (Brussels, Belgium) March 10, 2010 262) Antibiotic therapy: Optimal timing. 30

th International Symposium on Intensive

Care and Emergency Medicine. (Brussels, Belgium) March 11, 2010 263) Improving sepsis management: Speed is life. 30


Intensive Care and Emergency Medicine. (Brussels, Belgium) March 11, 2010 264) Unilateral Withdrawal: An 11th Commandment? Canadian Critical Care Conference (Whistler, BC) March 18, 2010 265) Panelist. Lessons from the H1N1 Pandemic in Canada. Canadian College of Health Service Executives/Health Professional’s Roundtable for Strategy Meeting. (New York, NY) April 15, 2010 266) Lessons from the Manitoba H1N1 Epidemic. The Critical Eye Nursing Conference. McPhillips Street Station. (Winnipeg, MB) April 19, 2010 267) Lessons from the Manitoba H1N1 epidemic. Roche Medical Advisory Board Meeting (Toronto, ON) April 19, 2010 268) Pandemic H1N1: From the front lines of the Winnipeg ICUs. Pan-infORM Workshop: The First Influenza Pandemic of the 21st Century: Canada's Response, Lessons Learned, and Challenges Ahead. National Biodiagnostics Institute (Winnipeg, MB) April 19, 2010 269) Speed is life: The role of rapid, appropriate antimicrobial therapy in outcome of septic shock. XLV Congresio Nationale de la SEMICYUC 2010. SEMICYUC:Spanish National Critical Care Society (Malaga, Spain) June 14, 2010. 270) Speed is life but a sledgehammer helps too: The importance of early pharmacokinetic/pharmacodynamic optimization in outcome of septic shock. XLV Congresio Nationale de la SEMICYUC 2010. SEMICYUC:Spanish National Critical Care Society (Malaga, Spain) June 14, 2010. 271) Pandemic H1N1: Lessons learned in the ICU. XLV Congresio Nationale de la SEMICYUC 2010. SEMICYUC:Spanish National Critical Care Society (Malaga, Spain) June 15, 2010. 272) H1N1 2009: The ICU Perspective. 50

th International Conference on Antimicrobial

Agents and Chemotherapy (ICAAC) (Boston, MA) Sept 12, 2010

81

273) Antimicrobial optimization in sepsis and septic shock. Pulmonary-Critical Care Grand Rounds, Wake-Forest University School of Medicine (Winston-Salem, NC) Oct 20, 2010 275) Optimizing outcomes in septic shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Moses-Cone Annual Critical Care Symposium: A Day of Critical Care (Greensboro, NC) Oct 21, 2010. 275) Mission Possible: “Killing bugs, disarming messengers”—Optimizing outcomes in sepsis with evidence-based antimicrobial therapy. Infectious Diseases Society of America Satellite Symposium (IDSA) (Vancouver, BC) Oct 22, 2010.

276) Monotherapy vs. combination therapy of sepsis. Advanced Course on ICU Infections. Winthrop University Hospital and Weill-Cornell Medical Center (New York, NY) Oct 25, 2010. 278) Speed is life: Optimizing antimicrobial therapy in septic shock. Symposium: Severe Sepsis Treatment: Is it Time? American College of Chest Physicians Annual Symposium (Vancouver, BC) Oct 31, 2010 279) Monotherapy vs combination therapy in septic shock. Critical Care Canada Forum (Toronto, ON) Nov 8, 2010 280) Speed is life but a hammer helps too. Critical Care Canada Forum (Toronto, ON) Nov 8, 2010 281) Pandemic H1N1: Lessons learned. Critical Care Canada Forum (Toronto, ON) Nov 8, 2010 282) Early pharmacokinetic/pharmacodynamic optimization of antimicrobials in the outcome of septic shock. Critical Care Canada Forum (Toronto, ON) Nov 10, 2010 283) Pandemic H1N1 Influenza: Lessons learned. Society of Critical Care Medicine Annual Refresher Course (San Diego, CA) Jan 14, 2011 284) Septic shock: why antimicrobial therapy matters. Society of Critical Care Medicine Annual Refresher Course (San Diego, CA) Jan 14, 2011 285) Sepsis and septic shock: State of the art. 16


Infections in the Critically Ill (Porto, Portugal) Feb 24, 2011 286) The need for early antimicrobial therapy in septic shock. 16

th International

Symposium on Infections in the Critically Ill (Porto, Portugal) Feb 25, 2011

82

287) Rational antibiotic use in the critically ill. American Thoracic Society State of the Art Annual Meeting (San Diego, CA) March 3, 2011 288) Meet the Professor. American Thoracic Society State of the Art Annual Meeting 2011 (San Diego, CA) March 3, 2011 289) Lessons from the Cooperative Antimicrobial Therapy of Septic Shock Database. Section of Critical Care Medicine, University of Manitoba, Research in Progress (Winnipeg, MB) March 16, 2011 290) The importance of timing of therapies in septic shock. American Thoracic Society Annual Scientific Symposium 2011 (Denver, CO) May 15, 2011 291) Hit hard and fast: Mono vs combination therapy. German Sepsis Society Meeting (Weimar, Germany) Sept 9, 2011 292) How I de-escalate antimicrobial therapy. German Sepsis Society Meeting (Weimar, Germany) Sept 9, 2011. 293) Critical care delivery in the 2009 influenza pandemic: practical lessons from Manitoba, Canada. In the Symposium: Influenza antivirals -new insights on disease management and control. 4

th ESWI (European Scientific Working Group on Influenza)

Conference (St. George’s Bay, Malta) Sept 13, 2011. 294) Speed is Life: Optimizing antimicrobial therapy in septic shock. American College of Chest Physicians Annual Scientific Symposium (Honolulu, Hawaii) Oct 24, 2011 295) Speed is life but a hammer helps too. New concepts in optimizing antimicrobial therapy in septic shock. Sepsis Congress India 2011 (New Delhi, India) Nov 11, 2011 296) Viral pneumonia management, Focus on pandemic H1N1 2009. Sepsis Congress India 2011 (New Delhi, India) Nov 12, 2011 297) Optimizing antimicrobial therapy of fungal sepsis/septic shock. Sepsis Congress India 2011 (New Delhi, India) Nov 12, 2011 298) Speed is Life: Optimizing antimicrobial therapy in septic shock. 38th Annual Critical Care Symposium (Portland, OR) Nov 16, 2011 299) A Hammer Helps Too: Optimizing outcomes by maximizing pathogen clearance in septic shock. 38th Annual Critical Care Symposium (Portland, OR) Nov 16, 2011 300) Optimizing Antimicrobials in Septic Shock (the Laboratory Program). Section of Critical Care Medicine, University of Manitoba, Research in Progress (Winnipeg, MB) Nov 24, 2011

83

301) Speed is life but a hammer helps too. New concepts in optimizing antimicrobial therapy in septic shock. Department of Medicine, University of Manitoba Grand Rounds (Winnipeg, MB) Dec 6, 2011 302) Optimizing Antimicrobials in Septic Shock (the Laboratory Program). Section of Infectious Diseases/Medical Microbiology, University of Manitoba, Research in Progress (Winnipeg, MB) Dec 15, 2011 303) Speed is Life: Optimizing antimicrobial therapy in septic shock. Victoria General Hospital (Winnipeg, MB) Jan 30, 2012 304) Speed is life: The role of rapid, appropriate antimicrobial therapy in outcome of septic shock. 8

th Annual Perioperative Medicine Meeting (Madrid, Spain) Feb 17, 2012

305) Speed is life but a sledgehammer helps too: The importance of early pharmacokinetic/ pharmacodynamic optimization in outcome of septic shock. 8

th

Annual Perioperative Medicine Meeting (Madrid, Spain) Feb 17, 2012 306) Optimization of antimicrobial therapy of septic shock: Hit hard and fast! German Anesthesiology Congress 2012 (Leipzig, Germany) May 6, 2012 307) Optimization of antimicrobial therapy of septic shock. Special Symposium on Infection in the ICU: What it important? (Berlin, Germany) May 7, 2012 308) Optimization of antimicrobial therapy of septic shock: Speed is life. Update on Sepsis 2012. University Clinic, Eppendorf (Hamburg, Germany) May 8, 2012 309) A sledgehammer helps too: Optimizing antimicrobial therapy in septic shock. Lebensbedrohliche Infektionen. (Dusseldorf, Germany) May 9, 2012 310) Optimization of antimicrobial therapy for septic shock. Hit hard and hit fast. Colloquium on Infection Control and Therapy. University of Heidelberg Clinic (Heidelberg, Germany) May 10, 2012 311) Optimization of antimicrobial therapy for septic shock. Hit hard and hit fast. Colloquium on Infection Control and Therapy: Bridging the Gap. (Frankfurt, Germany) May 11, 2012. 312) Optimization of antimicrobial therapy of septic shock. Infektiologie Update (Munich, Germany) May 12, 2012. 313) Optimizing antimicrobial therapy in septic shock. Hit hard and fast. Tuscany Critical Care Society Annual Meeting (Florence, Italy) June 13, 2012

84

314) Combination antibiotics and outcome of life-threatening bacterial Infections and septic shock. 52

nd Interscience Conference on Antimicrobial Agents and

Chemotherapy (San Francisco, CA) Sept 10, 2012 315) Treatment and outcome of septic shock in Winnipeg. Symposium on Treatment of Severe Infections and De-escalation Strategy of Antimicrobial Therapy (Winnipeg, MB) Sept 18, 2012 316) Therapy of sepsis. Symposium on Treatment of Severe Infections and De-escalation Strategy of Antimicrobial Therapy (Winnipeg, MB) Sept 18, 2012 317) Speed is life: Time matters in management of septic shock. American College of Chest Physicians Annual Scientific Symposium (Atlanta, Georgia) Oct 24, 2012 318) Infections in immunosuppressed patients. 30

th Chilean Critical Care Conference

(La Serena, Chile) Oct 25, 2012 319) Speed is life: the importance of early antimicrobial initiation in septic shock. 30

th

Chilean Critical Care Conference (La Serena, Chile) Oct 25, 2012 320) A hammer helps: the role of dose, pharmacokinetics and drug combinations in septic shock. 30

th Chilean Critical Care Conference (La Serena, Chile) Oct 26, 2012

321) Antimicrobial De-escalation. 30

th Chilean Critical Care Conference (La Serena,

Chile) Oct 26, 2012 322) The role of rapid source control in management of septic shock. Critical Care Canada Forum (Toronto, ON) Oct 29, 2012 323) Why delays of antimicrobial therapy delivery occur and how to correct them. Critical Care Canada Forum (Toronto, ON) Oct 31, 2012 324) Immune defects and infection risk: How to assess. Society of Critical Care Medicine Annual Scientific Symposium (San Juan, Puerto Rico) Jan 21, 2013 325) Optimizing antimicrobial therapy of septic shock: Speed is life. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 1, 2013 326) Candida Sepsis: Speed is life. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 1, 2013 327) Optimizing antimicrobial therapy of septic shock: A hammer helps too. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 1, 2013

85

328) Early goal directed therapy: Controversies and newer trials. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 1, 2013 329) Myocardial depression in sepsis. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 2, 2013 330) Clinical research in critical care: How to get started. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 2, 2013 331) Antimicrobial de-escalation in the infected ICU patient. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 3, 2013 332) How to perform a meta-analysis. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 4, 2013 333) Assessing a meta-analysis. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 5, 2013 334) Speed is life: Optimizing antimicrobial therapy of septic shock. Ruby Hall Clinic and Hospital (Pune, India) March 6, 2013

335) Speed is life: Optimizing antifungal therapy in candida septic shock. Lilavati Hospital & Research Centre (Mumbai, India) March 7, 2013 336) Speed is life: Optimizing antimicrobial therapy of septic shock. Tagore Hospital (Chennai, India) March 8, 2013

337) Speed is life: Optimizing antifungal therapy in candida septic shock. Apollo Hospital (Hyderabad, India) March 11, 2013 338) Speed is life: Optimizing antimicrobial therapy of septic shock. Mediciti Hospital (Hyderabad, India) March 11, 2013

339) Speed is life: Optimizing antifungal therapy in candida septic shock. Sir Gangaram Hospital (Delhi, India) March 12, 2013 340) Speed is life: Optimizing antimicrobial therapy of septic shock. Medanta Medicity Hospital (Delhi, India) March 12, 2013 341) Speed is life: Optimizing antimicrobial therapy of septic shock. Apollo Hospital (Ludhiana, India) March 13, 2013 342) Visionary Conversations: Global pandemic: Another Y2K or future apocalypse? University of Manitoba Medical School (Winnipeg, MB) April 17, 2013

http://peggy-w.hubpages.com/hub/Photos-of-bluebonnets-and-other-Texas-wildflowers-in-the-Spring

86

343) Optimizing antimicrobial therapy in septic shock. British Columbia Sepsis Network (Vancouver, BC) April 23, 2013 344) Optimizing antimicrobial therapy in septic shock. Windsor Respirology Update 2013 (Windsor, ON) April 25, 2013 345) Antimicrobial de-escalation in ICU. Winnipeg Regional Health Authority (WRHA) Critical Care Improvement Symposium (Winnipeg, MB) May 23, 2013 346) Optimizing antimicrobial therapy of septic shock. Calgary Critical Care Medicine Grand Grounds (Calgary, AB) May 29, 2013 347) Antibiotic De-escalation Strategies in the Critically Ill Infected Patient. 10the Sydney Short Course in Intensive Care Medicine (Sydney, Australia) July 24, 2013 348) Optimizing PK/PD antimicrobial parameters in critically ill patients with septic shock. Clinical Infectious Diseases Forum (Sydney, Australia) July 26, 2013 349) Strategies for achieving de-escalation of antimicrobial therapy in the critically ill. Clinical Infectious Diseases Forum (Sydney, Australia) July 27, 2013 350) The rationale for maximizing cidality in antimicrobial treatment of septic shock. Clinical Infectious Diseases Forum (Sydney, Australia) July 27, 2013 351) Causes and consequences of delays in appropriate antimicrobial therapy of septic shock. Royal Adelaide Hospital Medical Grand Rounds (Adelaide, Australia) July 29, 2013 352) When is combination Gram negative cover appropriate for critically ill patients? Australasian Society for Infectious Diseases. Gram Negative "Superbugs" Meeting 2013 (Gold Coast, Australia) August 2, 2013 353) Speed is life: Optimizing delivery of antimicrobial therapy in septic shock. Infectious Diseases Symposium, Westmead Hospital (Sydney, Australia) August 8, 2013 354) Combination antimicrobial therapy is unwarranted for gram positive and negative nosocomial sepsis. World Federation of Societies of Intensive and Critical Care Medicine 2013 Meeting, Durban Convention Center (Durban, South Africa) Aug 29, 2013 355) Antibiotics: an update. Optimizing pharmacokinetics. World Federation of Societies of Intensive and Critical Care Medicine 2013 Meeting, Durban Convention Center (Durban, South Africa) Aug 30, 2013

87

356) Epidemics: H1N1, lessons learned. World Federation of Societies of Intensive and Critical Care Medicine 2013 Meeting, Durban Convention Center (Durban, South Africa) Aug 30, 2013 357) Combination therapy for GNI: a better outcome? Federation of Societies of Intensive and Critical Care Medicine 2013 Meeting, Durban Convention Center (Durban, South Africa) Aug 30, 2013 358) Empirical antimicrobial therapy - combo vs. mono, combo is better. 6th International Congress of the German Sepsis Society (Weimar, Germany) Sept 5, 2013 359) Optimization of antimicrobial therapy in the context of septic shock – Hit hard and fast. 6th International Congress of the German Sepsis Society (Weimar, Germany) Sept 6, 2013 360) Why time matters: The role of urgency in treating sepsis. American College of Chest Physicians Annual Symposium (Chicago, IL) Oct 28, 2013 361) CVP is adequate for volume administration in sepsis. American College of Chest Physicians Annual Symposium (Chicago, IL) Oct 30, 2013 362) Optimization of antimicrobial therapy in the context of septic shock: Hit hard and fast. 18th Brazilian Congress of Intensive Care Medicine (Rio de Janeiro, Brazil) Nov 7, 2013 363) Pharmacokinetic considerations in antimicrobial management of septic shock. Hit hard and fast. 18th Brazilian Congress of Intensive Care Medicine (Rio de Janeiro, Brazil) Nov 7, 2013 364) Early antimicrobial therapy in nosocomial infections. When should it be fast? 18th Brazilian Congress of Intensive Care Medicine (Rio de Janeiro, Brazil) Nov 8, 2013 365) EGT: Newer trials, newer controversies. Canadian Critical Care Forum. (Toronto, ON) Nov 10, 2013 366) Assessing immune defects and infection risk. Canadian Critical Care Forum. (Toronto, ON) Nov 11, 2013 367) Lessons from the ICU: The Canadian H1N1 pandemic. Canadian Critical Care Forum. (Toronto, ON) Nov 12, 2013 368) Improving survival in septic shock patients through optimizing antimicrobial therapy. McGill Critical Care Medicine Grand Rounds. Montreal General Hospital. (Montreal, QC) Nov 29, 2013

88

369) Research in Septic Shock: Bench to Bedside. Critical Care Fellow Seminar. Montreal General Hospital (Montreal, QC) Nov 29, 2013 370) Optimizing antimicrobial therapy in septic shock: Speed is life. 52

nd Annual

Weil/University of California Symposium on Critical Care and Emergency Medicine. (Las Vegas, Nevada) April 4, 2014 371) Optimizing antimicrobial therapy in septic shock. A hammer helps too. 52

nd

Annual Weil/University of California Symposium on Critical Care and Emergency Medicine. (Las Vegas, Nevada) April 5, 2014 372) Antimicrobial De-escalation…can it improve outcome? 52

nd Annual Weil/University

of California Symposium on Critical Care and Emergency Medicine. (Las Vegas, Nevada) April 5, 2014 373) Update on influenza: 2014. 52

nd Annual Weil/University of California Symposium

on Critical Care and Emergency Medicine. (Las Vegas, Nevada) April 6, 2014 374) Ebola and Other Hemorrhagic Fevers. City-wide Anesthesia Grand Rounds. University of Manitoba (Winnipeg, MB) September 3, 2014 375) Appropriate Anti-Infective Therapy in the ICU: Can We Do Better? 54

th

Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Symposium (Washington, DC) September 8, 2014 376) Update in Septic Shock in Trauma Patients. 24

th Argentinian Congress on

Intensive Therapy (Mar del Plata, Argentina) September 18, 2014 377) The Heart in Sepsis. 24

th Argentinian Congress on Intensive Therapy (Mar del

Plata, Argentina) September 18, 2014 378) Optimizing Antimicrobials in Obese and Elderly Patients. 24

th Argentinian

Congress on Intensive Therapy (Mar del Plata, Argentina) September 19, 2014 379) Inotrope Selection in Septic Shock. 24

th Argentinian Congress on Intensive

Therapy (Mar del Plata, Argentina) September 20, 2014 380) AKI in Patients with Septic Shock. Diagnosis and Treatment. 24

th Argentinian

Congress on Intensive Therapy (Mar del Plata, Argentina) September 20, 2014 381) Obese Patients with Sepsis: Clinical Characteristics and Outcome. 24

th

Argentinian Congress on Intensive Therapy (Mar del Plata, Argentina) September 21, 2014

89

382) Importance of PK/PD Aspects of Antimicrobial Therapy in Septic Shock. 24th

Argentinian Congress on Intensive Therapy (Mar del Plata, Argentina) September 21, 2014 383) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. The 10th Annual Infectious Diseases/Critical Care Pharmacotherapy Conference on Contemporary Issues in the Management of Infections (Toronto, ON) Sept 27, 2014 384) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock II. University of Toronto Continuing Medical Education (Toronto, ON) Sept 28, 2014 385) Monitoring Volume Status and Giving Fluids After Early Goal-Directed Therapy. American College of Chest Physicians Annual Scientific Symposium (Austin TX) Oct 26, 2014 386) Antimicrobials: Nothing Else Matters. Canadian Critical Care Forum (Toronto, ON) Oct 30, 2014 387) The ROSII RCT - Low vs. High-Dose Oseltamivir in H1N1. Canadian Critical Care Forum (Toronto, ON) Oct 30, 2014 388) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Antimicrobial Stewardship: Current Challenges and Concerns Biomedis CME (Cebu City, Philippines) Nov 7, 2014 389) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Antimicrobial Stewardship: Current Challenges and Concerns Biomedis CME (Manila, Philippines) Nov 9, 2014 390) Optimizing antimicrobial therapy in septic shock: Speed is life. University of Washington Medicine Regional Sepsis Conference (Seattle, WA) March 6, 2015 391) Optimizing antimicrobial therapy in septic shock: A hammer helps too. University of Washington Medicine Regional Sepsis Conference (Seattle, WA) March 6, 2015 392) Heterogeneity in Sepsis: Pathogen and Infection Site. American Thoracic Society Annual International Conference (Denver, CO) May 17, 2015 393) Speed is Life: Optimizing antimicrobial therapy in septic shock. Critical Care Department, US National Institutes of Health Clinical Center (Bethesda, MD) June 17, 2015 394) Optimizing antimicrobial therapy of septic shock: Single ultra-high dose therapy of aminoglycosides in a rat model. Critical Care Department, US National Institutes of Health Clinical Center (Bethesda, MD) June 17, 2015

90

395) Speed is Life: Optimizing antimicrobial therapy in septic shock. Hospital Militar Grand Rounds (San Salvador, El Salvador) June 23, 2015 396) Speed is Life: Optimizing antimicrobial therapy in septic shock. El Salvador National Intensive and Acute Care Conference (San Salvador, El Salvador) June 25, 2015 397) Optimizing antimicrobial therapy in septic shock: A hammer helps too. El Salvador National Intensive and Acute Care Conference (San Salvador, El Salvador) June 25, 2015 398) Speed is Life: Optimizing antimicrobial therapy in septic shock. Hospital de Diagnostico (San Salvador, El Salvador) June 26, 2015 399) Speed is Life: Optimizing antimicrobial therapy in septic shock. Critical Care Medicine Sepsis Symposium, Cleveland Clinic (Cleveland, OH) August 14, 2015 400) Optimizing antimicrobial therapy in septic shock: A hammer helps too. Critical Care Medicine Sepsis Symposium, Cleveland Clinic (Cleveland, OH) August 14, 2015

401) The Heparin Anticoagulation for Sepsis (HALO) Study. Global Forum on Research

and Innovation for Health 2015 (Manila, Philippines) August 24, 2015

402) Speed is Life: Optimizing antimicrobial therapy in septic shock. BioMedis Critical

Care Symposium (Rochester, MN) Sept 4, 2015 403) Adequate Antimicrobial Therapy: Early vs Delayed? 8th International Congress of the German Sepsis Society (Jena, Germany) Sept 9, 2015 404) Sepsis Update 2015. Developing EM 2015 (Havana, Cuba) Sept 17, 2015 405) Emergency Management of Sepsis. Topics in ER and Hospitalist Care CPD Conference (Winnipeg, MB) Oct 9, 2015

406) Early antibiotics: A gold standard? Toronto Critical Care Forum (Toronto, ON) Oct

26, 2015

407) Pro: External Cooling Should Be Used in Febrile Septic Shock. American College of Chest Physicians Annual Scientific Symposium (Montreal, QC) Oct 27, 2015

408) Source control in septic shock. Toronto Critical Care Forum (Toronto, ON) Oct 28, 2015

91

409) Speed is Life: Optimizing antimicrobial delivery to improve outcomes in septic shock. Critical Care Conference (Madison, WI) Nov 2, 2015 410) Case management: Sepsis and septic shock. Department of Anesthesiology Case Conference (Madison, WI) Nov 2, 2015 411) Optimizing antimicrobial pharmacokinetics and pharmacodynamics in septic shock. Infectious Diseases Conference (Madison, WI) Nov 3, 2015 412) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock: Speed is Life. Critical Care Rounds, Medical College of Wisconsin (Milwaukee, WI) Nov 6, 2015 413) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock: Addressing PK and PD. Medical Grand Rounds, Medical College of Wisconsin (Milwaukee, WI) Nov 6, 2015 414) Optimizing Antimicrobial Therapy in Septic Shock (teleconference). Speed is Life. Midwest Critical Care Collaborative (Kansas City, KS) Dec 10, 2015 415) Timing of vasopressors in septic shock: How soon is too soon. 21

st Infection and

Sepsis Symposium (Porto, Portugal) March 7, 2016 416) EGDT is still a valid concept: Con. 21

st Infection and Sepsis Symposium (Porto,

Portugal) March 7, 2016 417) What is adequate source control in severe intra-abdominal infection. 21

st Infection

and Sepsis Symposium (Porto, Portugal) March 8, 2016 418) Speed is Life: Optimizing antimicrobial therapy in septic shock. University Grand Rounds (Manila, Philippines) March 17, 2016 419) Optimizing antimicrobial therapy in sepsis and septic shock. Grand Rounds of Marmara University School of Medicine (Istanbul, Turkey) June 5, 2016 420) Hammer Helps Too: Optimizing Antimicrobial Therapy of Septic Shock. ATTIKON University Hospital Grand Rounds (Athens, Greece) June 9, 2016 421) Speed is Life: Optimizing antimicrobial therapy in septic shock. Sepsis 2016 Conference (Athens, Greece) June 11, 2016 422) Goal-Directed Resuscitation of Septic Shock: Explaining Divergent Results. International Veterinary Emergency and Critical Care Symposium (Dallas, Texas) Sept 8, 2016

92

423) Septic Myocardial Depression. International Veterinary Emergency and Critical Care Symposium (Dallas, Texas) Sept 8, 2016 424) Speed is Life: Optimizing Antimicrobial Therapy in Septic Shock. International Veterinary Emergency and Critical Care Symposium (Dallas, Texas) Sept 8, 2016 425) A Hammer Helps Too: Optimizing Antimicrobial Therapy of Septic Shock. International Veterinary Emergency and Critical Care Symposium (Dallas, Texas) Sept 8, 2016 426) Speed is Life: Optimizing Antimicrobial Therapy in Septic Shock. Chinese Critical Care Congress 2016. Chinese (Dalian, China) Sept 23, 2016 427) Optimizing Antifungal Therapy in Sepsis and Septic Shock. Chinese Critical Care Congress 2016 (Dalian, China) Sept 24, 2016 428) Septic Shock and Renal Dysfunction: Relationship, Risk Factors and Treatment. Chinese Critical Care Congress 2016 (Dalian, China) Sept 24, 2016 429) Making Sense of Early Goal-Directed Therapy of Sepsis. Canadian Critical Care Forum 2016 (Toronto, Canada) Oct 31, 2016 430) Renal Function in Septic Shock: Lessons from the CATSS Database. Canadian Critical Care Forum 2016 (Toronto, Canada) Oct 31, 2016 431) Optimizing Septic Shock Outcome - Speed of source control. SepsEast 2016. 3

rd

Central and Eastern European Sepsis Forum (Budapest, Hungary) Nov 10, 2016 432) Speed is Life: Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Continuing Medical Education Conference, (Beijing, China) Nov 24, 2016 433) Speed is Life: Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Continuing Medical Education Conference, (Zhengzhou, China) Nov 25, 2016 434) Speed is Life: Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Continuing Medical Education Conference, (Guangzhou, China) Nov 26, 2016 435) Speed is Life: Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Continuing Medical Education Conference, (Shanghai, China) Nov 27, 2016 436) A Hammer Helps too: Optimizing Antimicrobials in Septic Shock. Hospital-wide Visiting Guest Lecture. Shanghai Zhongshan Hospital (Shanghai, China) April 19, 2017. 437) Severe Infections: Common Bacterial and Fungal Infections. SCCM Adult Multiprofessional Critical Care Board Review Course 2017 (Chicago, IL) July 28, 2017.

93

438) SCCM Adult Multiprofessional Critical Care Board Review Course 2017. Antibacterials, Antifungals, Antivirals: When, How Much and How Long? (Chicago, IL) July 28, 2017. 439) SCCM Adult Multiprofessional Critical Care Board Review Course 2017. Case Review: Sepsis (Chicago, IL) July 28, 2017. 440) Septic Shock: Optimizing Antimicrobials and Outcome in Surgical Cases. Cook County Trauma Rounds (Chicago, IL) July 28, 2017 441) Impact of the early start of antimicrobials in sepsis and septic shock. Argentine Society of Intensive Care (SATI) Annual 27

th National Conference (August 31, 2017)

Cordoba, Argentina 442) Antibiotics in sepsis: what, how and when?Argentine Society of Intensive Care (SATI) Annual 27

th National Conference (August 31, 2017) Cordoba, Argentina

443) Intra-abdominal infection: Optimized source control and antimicrobials. Argentine Society of Intensive Care (SATI) Annual 27

th National Conference (Sept 2, 2017)

Cordoba, Argentina 344) Bacterial load in sepsis and septic shock. 8

th International Congress of the

German Sepsis Society. 10th German Intensive Care Congress. (Jena, Germany) Sept

6, 2017.

anand kumar md - umanitoba.ca · anand kumar md current professor of medicine (2014 - present)...

Documents